<html lang="en" class="pb-page js" data-request-id="94d6f7851419128c-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6f7851419128c-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/u9emrTXw9MqeQ_yrVzeYuGxYAaG6tNGQ0mzHqJq-6OgerCKVVl2o3HsWbt74aezhWwjwwW1JCXq9p4Z8j1KV4Q=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Covid-19 Vaccine Protection among Children and Adolescents in Qatar | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6f7851419128c-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.8387936605170213"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Viral Infections|Vaccines|Coronavirus|Immunization">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease|Pediatrics"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2210058","title":"Covid-19 Vaccine Protection among Children and Adolescents in Qatar","category":"Research","type":"Original Article","topics":"Viral Infections|Vaccines|Coronavirus|Immunization","specialties":"Infectious Disease|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-11-17T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Vaccines|Coronavirus|Immunization\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease|Pediatrics\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2210058","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6f7851419128c-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Covid-19 Vaccine Protection among Children and Adolescents in Qatar"><meta name="dc.Creator" content="Hiam Chemaitelly"><meta name="dc.Creator" content="Sawsan AlMukdad"><meta name="dc.Creator" content="Houssein H. Ayoub"><meta name="dc.Creator" content="Heba N. Altarawneh"><meta name="dc.Creator" content="Peter Coyle"><meta name="dc.Creator" content="Patrick Tang"><meta name="dc.Creator" content="Hadi M. Yassine"><meta name="dc.Creator" content="Hebah A. Al-Khatib"><meta name="dc.Creator" content="Maria K. Smatti"><meta name="dc.Creator" content="Mohammad R. Hasan"><meta name="dc.Creator" content="Zaina Al-Kanaani"><meta name="dc.Creator" content="Einas Al-Kuwari"><meta name="dc.Creator" content="Andrew Jeremijenko"><meta name="dc.Creator" content="Anvar H. Kaleeckal"><meta name="dc.Creator" content="Ali N. Latif"><meta name="dc.Creator" content="Riyazuddin M. Shaik"><meta name="dc.Creator" content="Hanan F. Abdul-Rahim"><meta name="dc.Creator" content="Gheyath K. Nasrallah"><meta name="dc.Creator" content="Mohamed G. Al-Kuwari"><meta name="dc.Creator" content="Hamad E. Al-Romaihi"><meta name="dc.Creator" content="Adeel A. Butt"><meta name="dc.Creator" content="Mohamed H. Al-Thani"><meta name="dc.Creator" content="Abdullatif Al-Khal"><meta name="dc.Creator" content="Roberto Bertollini"><meta name="dc.Creator" content="Laith J. Abu-Raddad"><meta name="dc.Description" content="The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses.We..."><meta name="Description" content="The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses.We..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-11-17"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2210058"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202211173872010"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2210058">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2210058">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2210058">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Covid-19 Vaccine Protection among Children and Adolescents in Qatar | NEJM">
        <meta property="og:title" content="Covid-19 Vaccine Protection among Children and Adolescents in Qatar | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2210058">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/91b6836f-3fb0-4481-8cf3-bbe58abadb01/nejmoa2210058_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/91b6836f-3fb0-4481-8cf3-bbe58abadb01/nejmoa2210058_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized
for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but
in different antigen doses. W...">
        <meta name="twitter:description" content="The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized
for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but
in different antigen doses. W...">
    


    
    
        <meta property="og:image:width" content="2145">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2210058">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2210058">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2210058;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms;issue:issue:doi\:10.1056/nejm_2022.387.issue-20">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2210058" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2210058" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2210058" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2210058" class="inputDoi"><input type="hidden" value="H. Chemaitelly and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:1865-1876" class="inputCitation"><input type="hidden" value="11-02-2022" class="inputEPubDate"><input type="hidden" value="November 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Covid-19 Vaccine Protection among Children and Adolescents in Qatar" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6f7851419128c-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Covid-19 Vaccine Protection among Children and Adolescents in Qatar</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Hiam</span> <span property="familyName">Chemaitelly</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sawsan</span> <span property="familyName">AlMukdad</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Houssein H.</span> <span property="familyName">Ayoub</span>, <span property="honorificSuffix">Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2512-6657" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2512-6657</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Heba N.</span> <span property="familyName">Altarawneh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter</span> <span property="familyName">Coyle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Patrick</span> <span property="familyName">Tang</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1583-5484" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-1583-5484</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hadi M.</span> <span property="familyName">Yassine</span>, <span property="honorificSuffix">Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+17</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hebah A.</span> <span property="familyName">Al-Khatib</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maria K.</span> <span property="familyName">Smatti</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mohammad R.</span> <span property="familyName">Hasan</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zaina</span> <span property="familyName">Al-Kanaani</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Einas</span> <span property="familyName">Al-Kuwari</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew</span> <span property="familyName">Jeremijenko</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0375-2713" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0375-2713</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anvar H.</span> <span property="familyName">Kaleeckal</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ali N.</span> <span property="familyName">Latif</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9011-4391" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9011-4391</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Riyazuddin M.</span> <span property="familyName">Shaik</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hanan F.</span> <span property="familyName">Abdul-Rahim</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gheyath K.</span> <span property="familyName">Nasrallah</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mohamed G.</span> <span property="familyName">Al-Kuwari</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hamad E.</span> <span property="familyName">Al-Romaihi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adeel A.</span> <span property="familyName">Butt</span>, <span property="honorificSuffix">M.B., B.S.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1118-1826" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1118-1826</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mohamed H.</span> <span property="familyName">Al-Thani</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdullatif</span> <span property="familyName">Al-Khal</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Roberto</span> <span property="familyName">Bertollini</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Laith J.</span> <span property="familyName">Abu-Raddad</span>, <span property="honorificSuffix">Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0790-0506" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0790-0506</a></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-17</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">November 2, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">1865</span>-<span property="pageEnd">1876</span></div><div class="doi">DOI: 10.1056/NEJMoa2210058</div><div class="core-enumeration"><a href="/toc/nejm/387/20"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">20</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DHiam%2BChemaitelly%252C%2BSawsan%2BAlMukdad%252C%2BHoussein%2BH.%2BAyoub%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D20%26contentID%3D10.1056%252FNEJMoa2210058%26title%3DCovid-19%2BVaccine%2BProtection%2Bamong%2BChildren%2Band%2BAdolescents%2Bin%2BQatar%26publicationDate%3D11%252F17%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2210058" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DHiam%2BChemaitelly%252C%2BSawsan%2BAlMukdad%252C%2BHoussein%2BH.%2BAyoub%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D20%26contentID%3D10.1056%252FNEJMoa2210058%26title%3DCovid-19%2BVaccine%2BProtection%2Bamong%2BChildren%2Band%2BAdolescents%2Bin%2BQatar%26publicationDate%3D11%252F17%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d8e1d867-1a9d-4e89-8bbf-6f4ff1dcaf1f/nejmoa2210058.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2210058.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2210058" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2210058" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2210058.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We assessed the real-world effectiveness of the BNT162b2 vaccine against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children and adolescents in Qatar. To compare the incidence of SARS-CoV-2 infection in the national cohort of vaccinated participants with the incidence in the national cohort of unvaccinated participants, we conducted three matched, retrospective, target-trial, cohort studies — one assessing data obtained from children 5 to 11 years of age after the B.1.1.529 (omicron) variant became prevalent and two assessing data from adolescents 12 to 17 years of age before the emergence of the omicron variant (pre-omicron study) and after the omicron variant became prevalent. Associations were estimated with the use of Cox proportional-hazards regression models.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Among children, the overall effectiveness of the 10-μg primary vaccine series against infection with the omicron variant was 25.7% (95% confidence interval [CI], 10.0 to 38.6). Effectiveness was highest (49.6%; 95% CI, 28.5 to 64.5) right after receipt of the second dose but waned rapidly thereafter and was negligible after 3 months. Effectiveness was 46.3% (95% CI, 21.5 to 63.3) among children 5 to 7 years of age and 16.6% (95% CI, −4.2 to 33.2) among those 8 to 11 years of age. Among adolescents, the overall effectiveness of the 30-μg primary vaccine series against infection with the omicron variant was 30.6% (95% CI, 26.9 to 34.1), but many adolescents had been vaccinated months earlier. Effectiveness waned over time since receipt of the second dose. Effectiveness was 35.6% (95% CI, 31.2 to 39.6) among adolescents 12 to 14 years of age and 20.9% (95% CI, 13.8 to 27.4) among those 15 to 17 years of age. In the pre-omicron study, the overall effectiveness of the 30-μg primary vaccine series against SARS-CoV-2 infection among adolescents was 87.6% (95% CI, 84.0 to 90.4) and waned relatively slowly after receipt of the second dose.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Vaccination in children was associated with modest, rapidly waning protection against omicron infection. Vaccination in adolescents was associated with stronger, more durable protection, perhaps because of the larger antigen dose. (Funded by Weill Cornell Medicine–Qatar and others.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">The messenger RNA (mRNA) vaccine BNT162b2 (Pfizer–BioNTech) against coronavirus disease 2019 (Covid-19) has been authorized for use in adolescents 12 to 17 years of age and in children 5 to 11 years of age but in antigen doses of 30 μg and 10 μg, respectively.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2-1" href-manipulated="true">1,2</a></sup> Qatar launched mass Covid-19 immunization campaigns using these vaccines, first involving adolescents in several phases starting in February 2021 and then involving children 5 to 11 years of age starting in February 2022 (Section S1 in the <a href="#ap1">Supplementary Appendix</a>, available with the full text of this article at NEJM.org).</div><div role="paragraph">We assessed the real-world effectiveness of the two-dose primary vaccine series against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for the 10-μg dose of BNT162b2 vaccine among children and the 30-μg dose of BNT162b2 vaccine among adolescents. Assessment was part of a national study in Qatar, a country that has experienced five SARS-CoV-2 waves, dominated sequentially by the index virus,<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-1" href-manipulated="true" aria-label="Reference 3">3</a></sup> the B.1.1.7 (alpha) variant,<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4" href-manipulated="true" aria-label="Reference 4">4</a></sup> the B.1.351 (beta) variant,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5-1" href-manipulated="true" aria-label="Reference 5">5</a></sup> the B.1.1.529 (omicron) subvariants BA.1 and BA.2,<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6-1" href-manipulated="true" aria-label="Reference 6">6</a></sup> and the omicron subvariants BA.4 and BA.5,<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-1" href-manipulated="true" aria-label="Reference 7">7</a></sup> in addition to a prolonged low-incidence phase dominated by the B.1.617.2 (delta) variant.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-1" href-manipulated="true" aria-label="Reference 8">8</a></sup></div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Study Population and Data Sources</h3><div role="paragraph">We conducted this study in Qatar and analyzed data from the national, federated databases for Covid-19 laboratory testing, vaccination, hospitalization, and death, retrieved from the integrated, nationwide, digital-health information platform. These databases include all SARS-CoV-2–related data, such as results from all polymerase-chain-reaction (PCR) tests, and associated demographic information, with no missing information since the onset of the pandemic. The databases also include results from rapid antigen tests that were conducted at health care facilities starting from January 5, 2022. Rapid antigen test kits are available for purchase in pharmacies in Qatar, but outcomes of home-based testing are not reported or documented in the national databases and thus were not factored in our study, including in the estimations of cumulative incidence or incidence rate. Detailed descriptions of the population of Qatar and of the national databases have been reported previously.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r5 r6 r9 r10" id="body-ref-r10-1" href-manipulated="true">3,5,6,9,10</a></sup></div></section><section id="sec-1-2"><h3>Study Design and Cohorts</h3><div role="paragraph">Three matched, retrospective cohort studies emulating randomized target trials<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11" id="body-ref-r11" href-manipulated="true">10,11</a></sup> were conducted to investigate the effectiveness of the BNT162b2 vaccine among children 5 to 11 years of age and among adolescents 12 to 17 years of age at least 14 days after the receipt of the second vaccine dose. The target of estimation was the effect of being vaccinated among persons who received the vaccine; the average treatment effect among treated persons quantifies vaccine effectiveness among the subpopulation that was vaccinated.</div><div role="paragraph">In each study, the incidence of infection or of severe,<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-1" href-manipulated="true" aria-label="Reference 12">12</a></sup> critical,<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-2" href-manipulated="true" aria-label="Reference 12">12</a></sup> or fatal<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-1" href-manipulated="true" aria-label="Reference 13">13</a></sup> Covid-19 was compared between the national cohort of previously uninfected persons who had completed the two-dose BNT162b2 primary series (designated as the vaccinated cohort) and the national control cohort of persons who were previously uninfected and were unvaccinated (designated as the control cohort). The focus of the studies was on vaccine-related immunity and not on a hybrid immunity of previous infection and vaccination. Persons with a record of previous infection were excluded.</div><div role="paragraph">Documentation of infection was based on positive PCR or rapid antigen testing. Laboratory methods are presented in Section S2. To inform the national Covid-19 response in Qatar, 5% of positive cases are targeted for viral-genome sequencing, and a larger proportion is targeted for genotyping with the use of multiplex real-time reverse-transcriptase PCR variant screening. The classification of Covid-19 cases as being severe (acute care hospitalization),<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-3" href-manipulated="true" aria-label="Reference 12">12</a></sup> critical (hospitalization in the intensive care unit),<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-4" href-manipulated="true" aria-label="Reference 12">12</a></sup> or fatal<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-2" href-manipulated="true" aria-label="Reference 13">13</a></sup> followed World Health Organization guidelines (Section S3).</div></section><section id="sec-1-3"><h3>Cohort Matching and Follow-up</h3><div role="paragraph">Vaccinated persons were matched one to one with unvaccinated persons in the control cohort according to sex, age, nationality, and number of coexisting conditions (none, one, or two or more) in order to account for differences in SARS-CoV-2 exposure risk in Qatar.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r14 r15 r16 r17" id="body-ref-r17-1" href-manipulated="true">3,14–17</a></sup> Matching according to these factors was previously shown to provide adequate control of differences in exposure risk in Qatar.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r18 r19 r20 r21" id="body-ref-r21-1" href-manipulated="true">9,18–21</a></sup></div><div role="paragraph">Matching was also done according to the calendar month of receipt of the second vaccine dose for the vaccinated cohort and the calendar month of receipt of a SARS-CoV-2–negative test for the control cohort. That is, persons who received their second vaccine dose in a specific month were matched with unvaccinated persons who had a record of a SARS-CoV-2–negative test in that same calendar month, to ensure that these persons were in Qatar at the same time. Matching was performed iteratively such that persons in the control cohort were alive, infection-free, and unvaccinated at the start of follow-up.</div><div role="paragraph">Each matched pair was followed from the calendar day on which the vaccinated person had completed 14 days after receiving the second dose. To ensure exchangeability,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r22" id="body-ref-r22" href-manipulated="true">10,22</a></sup> data on both members of each matched pair were censored when the vaccinated participant received a third (booster) dose or when a control participant received a first dose of vaccine. Participants were followed until the first of any of the following events: documented SARS-CoV-2 infection (defined as the first positive PCR or rapid antigen test after the start of follow-up, regardless of the presence of symptoms), booster vaccination in participants who had received the primary vaccine series (with matched-pair censoring), receipt of the first dose of vaccine in control participants (with matched-pair censoring), death, or the end of the study. Many participants contributed follow-up time first as unvaccinated persons (before receipt of the first dose), while being matched with vaccinated persons, and subsequently contributed follow-up time as vaccinated persons (after receipt of the second dose) while being matched with unvaccinated persons. Allowing such crossover in the study design may reduce potential differences arising from unmeasured risk behaviors related to vaccination or infection status.</div></section><section id="sec-1-4"><h3>Omicron 10-μg BNT162b2 Study Involving Children</h3><div role="paragraph">In the omicron study involving children, we estimated the effectiveness of the pediatric 10-μg dose of the BNT162b2 vaccine against omicron infection among children 5 to 11 years of age.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r10" id="body-ref-r10-4" href-manipulated="true">6,10</a></sup> Virtually all cases of SARS-CoV-2 infection since the onset of the omicron wave have been due to omicron subvariants. Any child who had received two doses of vaccine between February 3, 2022 (earliest record of two-dose vaccination in children), and July 12, 2022 (end of study), was eligible for inclusion in the vaccinated cohort on day 14 after receipt of the second dose, provided that the child had no record of SARS-CoV-2 infection before the start of follow-up. Any child with a SARS-CoV-2–negative test during the study was eligible for inclusion in the control cohort, provided that the child had no record of infection or vaccination before the start of follow-up.</div></section><section id="sec-1-5"><h3>Pre-Omicron 30-μg BNT162b2 Study Involving Adolescents</h3><div role="paragraph">In the pre-omicron study, we estimated the effectiveness of the 30-μg dose of the BNT162b2 vaccine against SARS-CoV-2 infection before the emergence of the omicron variant (pre-omicron period) among adolescents 12 to 17 years of age. Any adolescent who had received two doses of the BNT162b2 vaccine between February 1, 2021 (earliest record of two-dose vaccination in adolescents), and November 30, 2021 (end of study), was eligible for inclusion in the vaccinated cohort, provided that the adolescent had no record of infection before the start of follow-up. Follow-up was from day 14 after receipt of the second dose until November 30, 2021 (first evidence of the omicron variant in Qatar<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r10" id="body-ref-r10-5" href-manipulated="true">6,10</a></sup>), to ensure that incidence was due to a pre-omicron variant. Any adolescent with a SARS-CoV-2–negative test during the study was eligible for inclusion in the control cohort, provided that the adolescent had no record of infection or vaccination before the start of follow-up.</div></section><section id="sec-1-6"><h3>Omicron 30-μg BNT162b2 Study Involving Adolescents</h3><div role="paragraph">In the omicron study involving adolescents 12 to 17 years of age, we estimated the effectiveness of the 30-μg dose of the BNT162b2 vaccine against infection with the omicron variant. Any adolescent who had received two doses of the BNT162b2 vaccine between February 1, 2021, and July 12, 2022 (end of study), was eligible for inclusion in the vaccinated cohort, provided that the adolescent had no record of infection or receipt of a third dose of vaccine before the start of follow-up. Follow-up was from December 19, 2021 (onset of the omicron wave in Qatar<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r10" id="body-ref-r10-6" href-manipulated="true">6,10</a></sup>), if the second dose of vaccine had been received at least 14 days before this date (i.e., before the omicron wave) and from day 14 after receipt of the second dose otherwise. Any adolescent with a SARS-CoV-2–negative test between February 1, 2021, and July 12, 2022, was eligible for inclusion in the control cohort, provided that the adolescent had no record of infection or vaccination before the start of follow-up. The study was replicated to estimate the effectiveness of a third (booster) 30-μg dose of the BNT162b2 vaccine against omicron infection among adolescents 12 to 17 years of age.</div></section><section id="sec-1-7"><h3>Oversight</h3><div role="paragraph">The institutional review boards at Hamad Medical Corporation and Weill Cornell Medicine–Qatar approved this retrospective study with a waiver of informed consent. The study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (Table S1). The authors vouch for the accuracy and completeness of the data and for the fidelity of the study to the protocol. The data set used in this study is the property of the Ministry of Public Health of Qatar and was provided to the researchers through a restricted-access agreement for the preservation of confidentiality of patient data. The funders had no role in the study design; the collection, analysis, or interpretation of the data; or the writing of the manuscript.</div></section><section id="sec-1-8"><h3>Statistical Analysis</h3><div role="paragraph">The eligible and matched cohorts were described with the use of frequency distributions and measures of central tendency; the study groups within the cohorts were compared with the use of standardized mean differences. A standardized mean difference of 0.1 or less indicated adequate matching. The Kaplan–Meier estimator method was used to estimate the cumulative incidence of infection, which was defined as the proportion of persons who became infected, out of those who were at risk; the primary end point during follow-up was a breakthrough infection in the vaccinated cohort or an infection in the control cohort. The incidence rate of infection in each cohort, defined as the number of identified infections divided by the number of person-weeks contributed by all persons in the cohort, was estimated, with a corresponding 95% confidence interval, with the use of a Poisson log-likelihood regression model with the <i>stptime</i> command in Stata software, version 17.0. Both the cumulative incidence and incidence rate were estimated strictly for infections that had been documented at health care facilities. These measures did not include the incidence of undiagnosed infections or of infections that were diagnosed on the basis of home-based testing.</div><div role="paragraph">Hazard ratios comparing the incidence of infection in the cohorts, along with their corresponding 95% confidence intervals, were calculated with the use of Cox regression with adjustment for the matching factors with the <i>stcox</i> command in Stata software, version 17.0. Schoenfeld residuals and log–log plots for survival curves were used to test the proportional-hazards assumption. Confidence intervals were not adjusted for multiplicity; thus, they should not be used to infer definitive differences between groups. Interactions were not considered. Vaccine effectiveness was estimated as 1 minus the adjusted hazard ratio and is presented as a percentage.</div><div role="paragraph">Effectiveness was also estimated against symptomatic infection. Subgroup analyses were conducted to investigate the durability of vaccine protection. Adjusted hazard ratios were calculated, with stratification according to the number of months since receipt of the second vaccine dose or according to subgroups of persons vaccinated at different times. Subgroup analyses were also conducted to investigate differences in vaccine protection according to year of age and according to age groups. The number needed to vaccinate to prevent one documented infection was calculated by dividing the number of vaccinated persons by the number of averted infections. The number of averted infections was estimated from the difference in the cumulative incidence curves. The incidence of vaccine-preventable infection was estimated as the vaccine effectiveness multiplied by the incidence rate among control participants.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup></div><div role="paragraph">Sensitivity analyses with adjustment for the effectiveness estimates for differences in testing frequency between cohorts were conducted. Statistical analyses were conducted with the use of Stata/SE software, version 17.0 (StataCorp).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Omicron 10-μg BNT162b2 Study Involving Children</h3><div role="paragraph">Figure S1 shows the process of selection of the study population. <a href="#t1">Table 1</a> describes the characteristics of the participants in the full study population and the matched cohorts. Each matched cohort included 18,728 children. The study was conducted in the total pediatric population of Qatar; thus, the study population is broadly representative of the pediatric population of Qatar (Table S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t1.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/896b4be1-fd3c-4e3f-b58a-b320b8a0f076/assets/images/large/nejmoa2210058_t1.jpg" height="2399" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Full Eligible Cohorts</span></th><th class="txxr-borders" colspan="3"><span>Matched Cohorts<a href="#t1fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vaccinated Cohort<br>(N=21,888)</th><th class="xxxx-borders">Control Cohort<br>(N=91,870)</th><th class="xxxx-borders">SMD<a href="#t1fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated Cohort<br>(N=18,728)</th><th class="xxxx-borders">Control Cohort<br>(N=18,728)</th><th class="xxxr-borders">SMD<a href="#t1fn3" role="doc-noteref">‡</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (IQR) — yr</td><td class="xxxx-borders">8 (7–10)</td><td class="xxxx-borders">8 (6–9)</td><td class="xxxx-borders">0.32<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">8 (7–10)</td><td class="xxxx-borders">8 (7–10)</td><td class="xxxr-borders">0.00<a href="#t1fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.36</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">5 yr</td><td class="xxxx-borders">1,874 (8.6)</td><td class="xxxx-borders">17,503 (19.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,802 (9.6)</td><td class="xxxx-borders">1,802 (9.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">6 yr</td><td class="xxxx-borders shading">2,768 (12.6)</td><td class="xxxx-borders shading">14,190 (15.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,512 (13.4)</td><td class="xxxx-borders shading">2,512 (13.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">7 yr</td><td class="xxxx-borders">3,175 (14.5)</td><td class="xxxx-borders">13,526 (14.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,769 (14.8)</td><td class="xxxx-borders">2,769 (14.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">8 yr</td><td class="xxxx-borders shading">3,381 (15.4)</td><td class="xxxx-borders shading">12,555 (13.7)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,850 (15.2)</td><td class="xxxx-borders shading">2,850 (15.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">9 yr</td><td class="xxxx-borders">3,331 (15.2)</td><td class="xxxx-borders">12,099 (13.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,847 (15.2)</td><td class="xxxx-borders">2,847 (15.2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">10 yr</td><td class="xxxx-borders shading">3,593 (16.4)</td><td class="xxxx-borders shading">10,903 (11.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,946 (15.7)</td><td class="xxxx-borders shading">2,946 (15.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">11 yr</td><td class="xxxx-borders">3,766 (17.2)</td><td class="xxxx-borders">11,094 (12.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,002 (16.0)</td><td class="xxxx-borders">3,002 (16.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.01</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Male</td><td class="xxxx-borders">11,026 (50.4)</td><td class="xxxx-borders">46,950 (51.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">9,374 (50.1)</td><td class="xxxx-borders">9,374 (50.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">10,862 (49.6)</td><td class="xxxx-borders shading">44,920 (48.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">9,354 (49.9)</td><td class="xxxx-borders shading">9,354 (49.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Nationality — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.18</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Bangladeshi</td><td class="xxxx-borders shading">567 (2.6)</td><td class="xxxx-borders shading">1,033 (1.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">373 (2.0)</td><td class="xxxx-borders shading">373 (2.0)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Egyptian</td><td class="xxxx-borders">718 (3.3)</td><td class="xxxx-borders">10,289 (11.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">718 (3.8)</td><td class="xxxx-borders">718 (3.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Filipino</td><td class="xxxx-borders shading">2,918 (13.3)</td><td class="xxxx-borders shading">2,123 (2.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1,542 (8.2)</td><td class="xxxx-borders shading">1,542 (8.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Indian</td><td class="xxxx-borders">12,822 (58.6)</td><td class="xxxx-borders">23,924 (26.0)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11,951 (63.8)</td><td class="xxxx-borders">11,951 (63.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nepalese</td><td class="xxxx-borders shading">144 (0.7)</td><td class="xxxx-borders shading">193 (0.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">76 (0.4)</td><td class="xxxx-borders shading">76 (0.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Pakistani</td><td class="xxxx-borders">1,227 (5.6)</td><td class="xxxx-borders">5,607 (6.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,190 (6.4)</td><td class="xxxx-borders">1,190 (6.4)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Qatari</td><td class="xxxx-borders shading">128 (0.6)</td><td class="xxxx-borders shading">18,921 (20.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">128 (0.7)</td><td class="xxxx-borders shading">128 (0.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Sri Lankan</td><td class="xxxx-borders">350 (1.6)</td><td class="xxxx-borders">1,096 (1.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">311 (1.7)</td><td class="xxxx-borders">311 (1.7)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Sudanese</td><td class="xxxx-borders shading">95 (0.4)</td><td class="xxxx-borders shading">2,837 (3.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">95 (0.5)</td><td class="xxxx-borders shading">95 (0.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Other<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">2,919 (13.3)</td><td class="xxxx-borders">25,847 (28.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,344 (12.5)</td><td class="xxxx-borders">2,344 (12.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of coexisting conditions — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.11</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">0</td><td class="xxxx-borders">17,954 (82.0)</td><td class="xxxx-borders">71,929 (78.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">16,030 (85.6)</td><td class="xxxx-borders">16,030 (85.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">3,345 (15.3)</td><td class="xxxx-borders shading">15,973 (17.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,362 (12.6)</td><td class="xxxx-borders shading">2,362 (12.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">≥2</td><td class="xbxx-borders">589 (2.7)</td><td class="xbxx-borders">3,968 (4.3)</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">336 (1.8)</td><td class="xbxx-borders">336 (1.8)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics of Children 5 to 11 Years of Age in the Study of Effectiveness of the 10-μg Dose of the BNT162b2 Vaccine against Infection with a SARS-CoV-2 Omicron Subvariant.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Shown are the baseline characteristics of the eligible and matched vaccinated and control cohorts in the study of the effectiveness of the 10-μg dose of the BNT162b2 vaccine against infection with a B.1.1.529 (omicron) subvariant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children 5 to 11 years of age. IQR denotes interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Vaccinated and control cohorts were matched in a 1:1 ratio according to sex, age, nationality, number of coexisting conditions, and calendar month of receipt of the second dose of vaccine for the vaccinated participant or the SARS-CoV-2–negative test for the control participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The standardized mean difference (SMD) is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD of 0.1 or less indicates adequate matching.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The SMD is for the mean difference between groups, divided by the pooled standard deviation.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Nationalities were chosen to represent the most populous groups in Qatar.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">This group included up to 140 other nationalities in the unmatched cohorts and 66 other nationalities in the matched cohorts.</div></div></div></figcaption></figure></div><div role="paragraph">The median follow-up was 69 days (interquartile range, 31 to 97) in the vaccinated cohort and 69 days (interquartile range, 30 to 97) in the control cohort (<a href="#f1">Figure 1A</a>). During follow-up, there were 184 infections in the vaccinated cohort and 248 infections in the control cohort. None of the infections progressed to severe, critical, or fatal Covid-19. The incidence of infection coincided with the time when cases were due to the omicron BA.1, BA.2, BA.4, and BA.5 subvariants but after the peak of the major wave of infections with the BA.1 and BA.2 subvariants in mid-January 2022.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r10" id="body-ref-r10-7" href-manipulated="true">6,7,10</a></sup> The cumulative incidence of infection at 110 days after the start of follow-up was 2.1% (95% confidence interval [CI], 1.7 to 2.4) in the vaccinated cohort and 2.4% (95% CI, 2.0 to 2.7) in the control cohort (<a href="#f1">Figure 1A</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f1.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/91b6836f-3fb0-4481-8cf3-bbe58abadb01/assets/images/large/nejmoa2210058_f1.jpg" height="3438" width="2145" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Omicron Infection in Children 5 to 11 Years of Age, According to Vaccination Status, and Effectiveness of the 10-μg Vaccine Dose.</div><div class="notes"><div role="doc-footnote">Panel A shows the cumulative incidence of infection with the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children 5 to 11 years of age who had received two 10-μg doses of the BNT162b2 vaccine, as compared with unvaccinated children (control). The inset shows the same data on an expanded y axis. Panel B shows the vaccine effectiveness against omicron infection among children who had received two 10-μg doses according to the number of months after the start of follow-up. Follow-up began 14 days after receipt of the second dose. The lower boundary of the 95% confidence interval (𝙸 bar) for the data at month 4 or later has been truncated.</div></div></figcaption></figure></div><div role="paragraph">The overall hazard ratio for infection, which was adjusted for sex, age, nationality group, number of coexisting conditions, and calendar month of the second vaccine dose or the SARS-CoV-2–negative test, was 0.74 (95% CI, 0.61 to 0.90) (<a href="#t2">Table 2</a>). The overall vaccine effectiveness against omicron infection was 25.7% (95% CI, 10.0 to 38.6). Effectiveness decreased with time after receipt of the second vaccine dose (<a href="#f1">Figure 1B</a>). Effectiveness was highest (49.6%; 95% CI, 28.5 to 64.5) right after receipt of the second dose but waned rapidly thereafter and was 11.0% (95% CI, −26.8 to 37.5) by the third month after receipt of the second dose.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t2.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/3eaf454a-306a-46e5-8a71-addba10edc20/assets/images/large/nejmoa2210058_t2.jpg" height="1748" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Epidemiologic Measure</th><th class="txxx-borders">Vaccinated<br>Cohort</th><th class="txxx-borders">Control<br>Cohort</th><th class="txxr-borders">Effectiveness<br>(95% CI)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Children 5–11 yr of age, omicron study</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total follow-up — no. of person-wk</td><td class="xxxx-borders">173,451</td><td class="xxxx-borders">173,082</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incidence rate of infection per 10,000 person-wk (95% CI)</td><td class="xxxx-borders shading">10.6 (9.2–12.3)</td><td class="xxxx-borders shading">14.3 (12.7–16.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hazard ratio for infection with an omicron subvariant (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unadjusted analysis</td><td class="xxxx-borders shading">0.74 (0.61–0.90)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">25.7 (10.0–38.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted analysis<a href="#t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0.74 (0.61–0.90)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">25.7 (10.0–38.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adolescents 12–17 yr of age, pre-omicron study</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total follow-up — no. of person-wk</td><td class="xxxx-borders">192,309</td><td class="xxxx-borders">185,751</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incidence rate of infection per 10,000 person-wk (95% CI)</td><td class="xxxx-borders shading">3.5 (2.7–4.4)</td><td class="xxxx-borders shading">28.2 (25.8–30.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hazard ratio for infection with a pre-omicron subvariant (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unadjusted analysis</td><td class="xxxx-borders shading">0.13 (0.10–0.16)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">87.5 (83.8–90.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted analysis<a href="#t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0.12 (0.10–0.16)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">87.6 (84.0–90.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adolescents 12–17 yr of age, omicron study</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total follow-up — no. of person-wk</td><td class="xxxx-borders">338,838</td><td class="xxxx-borders">319,291</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incidence rate of infection per 10,000 person-wk (95% CI)</td><td class="xxxx-borders shading">74.4 (71.5–77.3)</td><td class="xxxx-borders shading">104.5 (101.0–108.1)</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hazard ratio for infection with an omicron subvariant (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unadjusted analysis</td><td class="xxxx-borders shading">0.72 (0.69–0.76)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">27.7 (23.8–31.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Adjusted analysis<a href="#t2fn1" role="doc-noteref">*</a></td><td class="xbxx-borders">0.69 (0.66–0.73)</td><td class="xbxx-borders">—</td><td class="xbxr-borders">30.6 (26.9–34.1)</td></tr></tbody></table></div><figcaption><div class="caption">Effectiveness of the BNT162b2 Vaccine against SARS-CoV-2 Infection among Children and Adolescents in Qatar.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The Cox regression analysis was adjusted for sex, age, nationality, number of coexisting conditions, and calendar month of receipt of the second vaccine dose for the vaccinated participant or the SARS-CoV-2–negative test for the control participant.</div></div></div></figcaption></figure></div><div role="paragraph">Vaccine effectiveness was 46.3% (95% CI, 21.5 to 63.3) among children 5 to 7 years of age and 16.6% (95% CI, −4.2 to 33.2) among those 8 to 11 years of age. The median date of the second vaccine dose was April 14, 2022, among children 5 to 7 years of age and April 10, 2022, among those 8 to 11 years of age. Overall, effectiveness according to year of age showed a declining trend (Fig. S2A). Effectiveness against symptomatic infection was 36.9% (95% CI, −29.9 to 69.4). The number needed to vaccinate to prevent one infection was 333.3. The incidence rate of vaccine-preventable infection was 3.7 cases per 10,000 person-weeks.</div></section><section id="sec-2-2"><h3>Pre-Omicron 30-μg BNT162b2 Study Involving Adolescents</h3><div role="paragraph">Figure S3 shows the process of selection of the study population. <a href="#t3">Table 3</a> describes the characteristics of the participants in the full study population and the matched cohorts. Each matched cohort included 23,317 adolescents.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t3.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/0ff1ebcf-49d2-49c9-ade1-3018307b0630/assets/images/large/nejmoa2210058_t3.jpg" height="2599" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="6"><span>Pre-Omicron Study</span></th><th class="txxr-borders" colspan="6"><span>Omicron Study</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="3"><span>Full Eligible Cohorts</span></th><th class="xxxx-borders" colspan="3"><span>Matched Cohorts<a href="#t3fn2" role="doc-noteref">†</a></span></th><th class="xxxx-borders" colspan="3"><span>Full Eligible Cohorts</span></th><th class="xxxr-borders" colspan="3"><span>Matched Cohorts<a href="#t3fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=81,647)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=66,006)</th><th class="xxxx-borders">SMD<a href="#t3fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=23,317)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=23,317)</th><th class="xxxx-borders">SMD<a href="#t3fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=89,505)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=86,280)</th><th class="xxxx-borders">SMD<a href="#t3fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=17,903)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=17,903)</th><th class="xxxr-borders">SMD<a href="#t3fn3" role="doc-noteref">‡</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (IQR) — yr</td><td class="xxxx-borders">15 (14–16)</td><td class="xxxx-borders">14 (12–15)</td><td class="xxxx-borders">0.50<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">14 (13–16)</td><td class="xxxx-borders">14 (13–16)</td><td class="xxxx-borders">0.00<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">15 (13–16)</td><td class="xxxx-borders">14 (12–15)</td><td class="xxxx-borders">0.47<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">13 (12–15)</td><td class="xxxx-borders">13 (12–15)</td><td class="xxxr-borders">0.00<a href="#t3fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.71</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.00</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.64</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">12 yr</td><td class="xxxx-borders">3,174 (3.9)</td><td class="xxxx-borders">18,636 (28.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,767 (11.9)</td><td class="xxxx-borders">2,767 (11.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">7,865 (8.8)</td><td class="xxxx-borders">28,852 (33.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">6,003 (33.5)</td><td class="xxxx-borders">6,003 (33.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">13 yr</td><td class="xxxx-borders shading">16,581 (20.3)</td><td class="xxxx-borders shading">11,190 (17.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5,767 (24.7)</td><td class="xxxx-borders shading">5,767 (24.7)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">17,713 (19.8)</td><td class="xxxx-borders shading">13,530 (15.7)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,389 (18.9)</td><td class="xxxx-borders shading">3,389 (18.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">14 yr</td><td class="xxxx-borders">16,427 (20.1)</td><td class="xxxx-borders">10,382 (15.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">4,535 (19.4)</td><td class="xxxx-borders">4,535 (19.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">17,218 (19.2)</td><td class="xxxx-borders">12,403 (14.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,677 (15.0)</td><td class="xxxx-borders">2,677 (15.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">15 yr</td><td class="xxxx-borders shading">15,675 (19.2)</td><td class="xxxx-borders shading">9,861 (14.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,870 (16.6)</td><td class="xxxx-borders shading">3,870 (16.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">16,259 (18.2)</td><td class="xxxx-borders shading">11,866 (13.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,254 (12.6)</td><td class="xxxx-borders shading">2,254 (12.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">16 yr</td><td class="xxxx-borders">14,998 (18.4)</td><td class="xxxx-borders">8,257 (12.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,734 (11.7)</td><td class="xxxx-borders">2,734 (11.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">15,447 (17.3)</td><td class="xxxx-borders">10,136 (11.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,790 (10.0)</td><td class="xxxx-borders">1,790 (10.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">17 yr</td><td class="xxxx-borders shading">14,792 (18.1)</td><td class="xxxx-borders shading">7,680 (11.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,644 (15.6)</td><td class="xxxx-borders shading">3,644 (15.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">15,003 (16.8)</td><td class="xxxx-borders shading">9,493 (11.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1,790 (10.0)</td><td class="xxxx-borders shading">1,790 (10.0)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.00</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">41,919 (51.3)</td><td class="xxxx-borders shading">34,594 (52.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">12,083 (51.8)</td><td class="xxxx-borders shading">12,083 (51.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">45,936 (51.3)</td><td class="xxxx-borders shading">44,941 (52.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">9,258 (51.7)</td><td class="xxxx-borders shading">9,258 (51.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Female</td><td class="xxxx-borders">39,728 (48.7)</td><td class="xxxx-borders">31,412 (47.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11,234 (48.2)</td><td class="xxxx-borders">11,234 (48.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">43,569 (48.7)</td><td class="xxxx-borders">41,339 (47.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8,645 (48.3)</td><td class="xxxx-borders">8,645 (48.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Nationality — no. (%)<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.26</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.00</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.24</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Bangladeshi</td><td class="xxxx-borders">1,054 (1.3)</td><td class="xxxx-borders">967 (1.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">391 (1.7)</td><td class="xxxx-borders">391 (1.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,182 (1.3)</td><td class="xxxx-borders">1,521 (1.8)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">414 (2.3)</td><td class="xxxx-borders">414 (2.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Egyptian</td><td class="xxxx-borders shading">8,894 (10.9)</td><td class="xxxx-borders shading">7,538 (11.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,379 (14.5)</td><td class="xxxx-borders shading">3,379 (14.5)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">9,835 (11.0)</td><td class="xxxx-borders shading">9,460 (11.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,051 (11.5)</td><td class="xxxx-borders shading">2,051 (11.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Filipino</td><td class="xxxx-borders">3,029 (3.7)</td><td class="xxxx-borders">1,118 (1.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">280 (1.2)</td><td class="xxxx-borders">280 (1.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,372 (3.8)</td><td class="xxxx-borders">1,896 (2.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">345 (1.9)</td><td class="xxxx-borders">345 (1.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Indian</td><td class="xxxx-borders shading">12,943 (15.9)</td><td class="xxxx-borders shading">6,569 (10.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,812 (12.1)</td><td class="xxxx-borders shading">2,812 (12.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">15,084 (16.9)</td><td class="xxxx-borders shading">9,434 (10.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,735 (15.3)</td><td class="xxxx-borders shading">2,735 (15.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Nepalese</td><td class="xxxx-borders">102 (0.1)</td><td class="xxxx-borders">46 (0.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">9 (&lt;0.1)</td><td class="xxxx-borders">9 (&lt;0.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">120 (0.1)</td><td class="xxxx-borders">76 (0.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">7 (&lt;0.1)</td><td class="xxxx-borders">7 (&lt;0.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Pakistani</td><td class="xxxx-borders shading">5,089 (6.2)</td><td class="xxxx-borders shading">2,876 (4.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">982 (4.2)</td><td class="xxxx-borders shading">982 (4.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5,622 (6.3)</td><td class="xxxx-borders shading">3,932 (4.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1,051 (5.9)</td><td class="xxxx-borders shading">1,051 (5.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Qatari</td><td class="xxxx-borders">22,927 (28.1)</td><td class="xxxx-borders">22,196 (33.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">7,531 (32.3)</td><td class="xxxx-borders">7,531 (32.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">24,210 (27.0)</td><td class="xxxx-borders">26,578 (30.8)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">5,024 (28.1)</td><td class="xxxx-borders">5,024 (28.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Sri Lankan</td><td class="xxxx-borders shading">603 (0.7)</td><td class="xxxx-borders shading">260 (0.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">73 (0.3)</td><td class="xxxx-borders shading">73 (0.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">700 (0.8)</td><td class="xxxx-borders shading">494 (0.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">100 (0.6)</td><td class="xxxx-borders shading">100 (0.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Sudanese</td><td class="xxxx-borders">3,130 (3.8)</td><td class="xxxx-borders">2,253 (3.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">829 (3.6)</td><td class="xxxx-borders">829 (3.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,395 (3.8)</td><td class="xxxx-borders">2,855 (3.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">616 (3.4)</td><td class="xxxx-borders">616 (3.4)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other<a href="#t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">23,876 (29.2)</td><td class="xxxx-borders shading">22,183 (33.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">7,031 (30.2)</td><td class="xxxx-borders shading">7,031 (30.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">25,985 (29.0)</td><td class="xxxx-borders shading">30,034 (34.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5,560 (31.1)</td><td class="xxxx-borders shading">5,560 (31.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">No. of coexisting conditions — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.00</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.06</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">64,614 (79.1)</td><td class="xxxx-borders shading">52,741 (79.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">19,183 (82.3)</td><td class="xxxx-borders shading">19,183 (82.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">71,144 (79.5)</td><td class="xxxx-borders shading">70,646 (81.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">15,185 (84.8)</td><td class="xxxx-borders shading">15,185 (84.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">1 or 2</td><td class="xxxx-borders">13,478 (16.5)</td><td class="xxxx-borders">10,344 (15.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,309 (14.2)</td><td class="xxxx-borders">3,309 (14.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">14,592 (16.3)</td><td class="xxxx-borders">12,239 (14.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,208 (12.3)</td><td class="xxxx-borders">2,208 (12.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">≥3</td><td class="xbxx-borders shading">3,555 (4.4)</td><td class="xbxx-borders shading">2,921 (4.4)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">825 (3.5)</td><td class="xbxx-borders shading">825 (3.5)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">3,769 (4.2)</td><td class="xbxx-borders shading">3,395 (3.9)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">510 (2.8)</td><td class="xbxx-borders shading">510 (2.8)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics of Adolescents 12 to 17 Years of Age in Two Studies of Effectiveness of the 30-μg Dose of the BNT162b2 Vaccine.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Shown are the baseline characteristics of the eligible and matched cohorts in the studies of the effectiveness of the 30-μg dose of the BNT162b2 vaccine among adolescents 12 to 17 years of age against infection with a pre-omicron variant of SARS-CoV-2 and against infection with an omicron subvariant.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Vaccinated and control cohorts were matched in a 1:1 ratio according to sex, age, nationality, number of coexisting conditions, and calendar month of receipt of the second vaccine dose for the vaccinated participant or the SARS-CoV-2–negative test for the control participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">The SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD of 0.1 or less indicates adequate matching.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">The SMD is for the mean difference between groups, divided by the pooled standard deviation.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">Nationalities were chosen to represent the most populous groups in Qatar.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">In the pre-omicron study, this group included up to 135 other nationalities in the unmatched cohorts and 75 other nationalities in the matched cohorts. In the omicron study, this group included up to 143 other nationalities in the unmatched cohorts and 73 other nationalities in the matched cohorts.</div></div></div></figcaption></figure></div><div role="paragraph">The median follow-up was 45 days (interquartile range, 16 to 88) in the vaccinated cohort and 43 days (interquartile range, 15 to 85) in the control cohort (<a href="#f2">Figure 2A</a>). During follow-up, there were 67 infections in the vaccinated cohort and 523 infections in the control cohort. None of the infections progressed to severe, critical, or fatal Covid-19. Infections coincided with the time that the alpha, beta, and especially delta variants were predominant.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r24" id="body-ref-r24" href-manipulated="true">8,9,24</a></sup> The cumulative incidence of infection at 135 days after the start of follow-up was 0.8% (95% CI, 0.6 to 1.0) in the vaccinated cohort and 4.1% (95% CI, 3.7 to 4.6) in the control cohort (<a href="#f2">Figure 2A</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f2.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/2ca9a283-76fc-4f52-8285-094e6aba8277/assets/images/large/nejmoa2210058_f2.jpg" height="3100" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">SARS-CoV-2 Infection in Adolescents 12 to 17 Years of Age, According to Vaccination Status, in the Pre-Omicron and Omicron Studies.</div><div class="notes"><div role="doc-footnote">Shown is the cumulative incidence of SARS-CoV-2 infection among adolescents 12 to 17 years of age who had received two 30-μg doses of the BNT162b2 vaccine, as compared with unvaccinated adolescents (control) in studies assessing data during the period before the omicron variant became prevalent (pre-omicron study, Panel A) and after the omicron variant became prevalent (omicron study, Panel B). In both panels, the inset shows the same data on an enlarged y axis.</div></div></figcaption></figure></div><div role="paragraph">The overall adjusted hazard ratio for infection was 0.12 (95% CI, 0.10 to 0.16) (<a href="#t2">Table 2</a>). The overall vaccine effectiveness against pre-omicron infection was 87.6% (95% CI, 84.0 to 90.4). Effectiveness decreased with time after receipt of the second vaccine dose (<a href="#f3">Figure 3A</a>). Effectiveness was highest (95.3%; 95% CI, 92.0 to 97.2) right after the second dose but waned slowly thereafter.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f3.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/99857305-9cd9-40c7-8e7b-5ff57b20ddcb/assets/images/large/nejmoa2210058_f3.jpg" height="3438" width="2014" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Effectiveness of the 30-μg Vaccine Dose in Adolescents 12 to 17 Years of Age before and after the Emergence of the Omicron Variant.</div><div class="notes"><div role="doc-footnote">Panel A shows the effectiveness of the 30-μg dose of BNT162b2 vaccine against SARS-CoV-2 infection before the emergence of the omicron variant (pre-omicron study) among adolescents according to the number of months after receipt of the second dose. Follow-up began 14 days after receipt of the second dose. The lower boundary of the 95% confidence interval (𝙸 bar) for the data at month 4 has been truncated. Panel B shows the effectiveness of the 30-μg dose against omicron infection among adolescents according to date of receipt of the second dose. The date groups are shown in the order of increasing time since receipt of the second dose. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></figure></div><div role="paragraph">Vaccine effectiveness was 89.4% (95% CI, 84.5 to 92.7) among adolescents 12 to 14 years of age and 85.7% (95% CI, 79.7 to 89.8) among those 15 to 17 years of age. The median date of the second vaccine dose was August 23, 2021, among adolescents 12 to 14 years of age and July 14, 2021, among those 15 to 17 years of age. Effectiveness according to year of age was stable (Fig. S2B). Effectiveness against symptomatic infection was 91.2% (95% CI, 84.8 to 94.9). The number needed to vaccinate to prevent one infection was 30.3. The incidence rate of vaccine-preventable infection was 24.7 cases per 10,000 person-weeks.</div></section><section id="sec-2-3"><h3>Omicron 30-μg BNT162b2 Study Involving Adolescents</h3><div role="paragraph">Figure S4 shows the process of selection of the study population. <a href="#t3">Table 3</a> describes the characteristics of the participants in the full study population and the matched cohorts. Each matched cohort included 17,903 adolescents.</div><div role="paragraph">The median follow-up was 162 days (interquartile range, 48 to 205) in the vaccinated cohort and 149 days (interquartile range, 34 to 205) in the control cohort (<a href="#f2">Figure 2B</a>). During follow-up, there were 2520 infections in the vaccinated cohort, of which 1 progressed to critical Covid-19, and 3337 infections in the control cohort, of which 1 progressed to severe Covid-19 and another to critical Covid-19. The incidence of infection coincided initially with the major wave of infections caused by the omicron BA.1 and BA.2 subvariants in January 2022 (<a href="#f2">Figure 2B</a>).<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r10" id="body-ref-r10-8" href-manipulated="true">6,10</a></sup> Subsequently, the incidence of infection was due to the omicron BA.1, BA.2, BA.4, or BA.5 subvariants.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r10" id="body-ref-r10-9" href-manipulated="true">6,7,10</a></sup> The cumulative incidence of infection at 195 days after the start of follow-up was 15.9% (95% CI, 15.3 to 16.4) in the vaccinated cohort and 20.7% (95% CI, 20.1 to 21.3) in the control cohort (<a href="#f2">Figure 2B</a>).</div><div role="paragraph">The overall adjusted hazard ratio for infection was 0.69 (95% CI, 0.66 to 0.73) (<a href="#t2">Table 2</a>). The overall vaccine effectiveness against omicron infection was 30.6% (95% CI, 26.9 to 34.1). Effectiveness decreased with time after receipt of the second dose (<a href="#f3">Figure 3B</a>). It was highest (51.3%; 95% CI, 34.9 to 63.6) among participants who had received their second dose most recently (between January 1, 2022, and July 12, 2022) but was negligible (−1.7%; 95% CI, −16.9 to 11.5) among those who had completed their primary series between February 1, 2021, and June 30, 2021. The overall vaccine effectiveness was 35.5% (95% CI, 5.2 to 56.1) among adolescents who had been vaccinated between February 3, 2022, and July 12, 2022, which is the same time period during which vaccination was rolled out for children 5 to 11 years of age.</div><div role="paragraph">Vaccine effectiveness was 35.6% (95% CI, 31.2 to 39.6) among adolescents 12 to 14 years of age and 20.9% (95% CI, 13.8 to 27.4) among those 15 to 17 years of age. The median date of the second vaccine dose was November 11, 2021, among adolescents 12 to 14 years of age and September 19, 2021, among those 15 to 17 years of age. Effectiveness according to year of age showed a declining trend (Fig. S2C). Effectiveness against symptomatic infection was 43.6% (95% CI, 35.1 to 50.9). The number needed to vaccinate to prevent one infection was 20.8. The incidence rate of vaccine-preventable infection was 32.0 cases per 10,000 person-weeks. Despite the lower vaccine effectiveness against omicron infection than against infection with a pre-omicron variant, many infections were averted by vaccination owing to the very high incidence of infection during the omicron BA.1 and BA.2 wave.</div><div role="paragraph">Figure S5 shows the process for selecting the study population for the additional analysis to estimate booster effectiveness. Table S3 describes the characteristics of the participants in the full study population and the matched cohorts. In this additional analysis, the overall vaccine effectiveness against omicron infection was 36.7% (95% CI, 24.6 to 46.9). The cumulative-incidence curves suggested a rapid waning of effectiveness 4 months after receipt of the booster dose (Fig. S6).</div></section><section id="sec-2-4"><h3>Sensitivity Analyses and Crossover Design</h3><div role="paragraph">Sensitivity analyses with adjustment for differences in testing frequency between study groups in the three cohort studies yielded results that were similar to those of primary analyses (Table S4). Across the three studies, the percentage of participants in the vaccinated cohorts who contributed follow-up time as also unvaccinated ranged between 7.0% and 11.3%.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The 10-μg dose of the BNT162b2 vaccine in children was associated with only modest protection against omicron infection, with a vaccine effectiveness of approximately 25%. This protection was also short-lived, decreasing from approximately 50% right after receipt of the second dose to negligible levels after 3 months. However, the 30-μg dose of the BNT162b2 vaccine in adolescents was associated with stronger protection against omicron infection and with slower waning. The protection that was associated with this dose was approximately 30%, but some of the adolescents had been vaccinated months earlier. The vaccine effectiveness would have been higher in closer proximity to the second dose. Among adolescents who had been vaccinated concurrently with children, protection was approximately 35%. These findings suggest that the antigen dose is a determinant in the effectiveness of the vaccine. This effect remains to be investigated directly by comparison of the dose effects in same-age children or in same-age adolescents. The effectiveness of the booster dose among adolescents showed a similar level and pattern to that of the primary vaccine series.</div><div role="paragraph">Protection with the 30-μg dose of BNT162b2 among adolescents was stronger against pre-omicron infection than against omicron infection and waned slowly. Protection was approximately 95% right after receipt of the second dose and remained strong at more than 50% for at least 5 months. Overall, the protection and waning patterns that were associated with the 30-μg dose among adolescents paralleled those among adults,<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r9 r25" id="body-ref-r25" href-manipulated="true">6,9,25</a></sup> although protection seemed to be slightly stronger among adolescents than among adults.</div><div role="paragraph">Protection against omicron infection was higher among younger participants than among older participants. Protection was approximately 45% among children 5 to 7 years of age but was only approximately 15% among those 8 to 11 years of age, although the median vaccination date was similar in the two cohorts. Protection was approximately 35% among adolescents 12 to 14 years of age but was only approximately 20% among those 15 to 17 years of age, with the caveat that the cohort of those 15 to 17 years of age had a median vaccination date that was 2 months earlier than that for the cohort of those 12 to 14 years of age. The study findings are consistent with evidence about vaccine protection among children and adolescents in other countries.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r26 r27 r28 r29 r30" id="body-ref-r30-1" href-manipulated="true">2,26–30</a></sup></div><div role="paragraph">Our study has limitations. With the lower severity of SARS-CoV-2 infection among children than among adults<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29 r31" id="body-ref-r31" href-manipulated="true">29,31</a></sup> and the lower severity of omicron infections than infections with pre-omicron variants,<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32 r33" id="body-ref-r33" href-manipulated="true">32,33</a></sup> too few severe,<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-5" href-manipulated="true" aria-label="Reference 12">12</a></sup> critical,<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-6" href-manipulated="true" aria-label="Reference 12">12</a></sup> or fatal<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-3" href-manipulated="true" aria-label="Reference 13">13</a></sup> cases of Covid-19 were observed for us to estimate the vaccine effectiveness against severe Covid-19. Other studies have shown high vaccine effectiveness against severe Covid-19 among children and adolescents.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r34 r35 r36" id="body-ref-r36" href-manipulated="true">30,34–36</a></sup></div><div role="paragraph">We investigated the incidence of documented infections and defined our cohorts as being previously uninfected on the basis of an absence of a record of previous infection, but other infections may have occurred and gone undocumented. Some members of the cohorts may have had a previous infection that was never documented. Testing frequency differed between the cohorts, mainly owing to different testing guidelines for travel for vaccinated persons as compared with unvaccinated persons, but sensitivity analyses that were conducted with adjustment for these differences showed overall findings that were similar to those of the primary analyses (Table S4). Home-based rapid antigen testing is not documented and thus was not factored in our analyses. However, it is unlikely that home-based testing would have had a differential effect on the followed cohorts. Matching was done to control for confounders that are known to affect infection exposure in Qatar,<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r14 r15 r16 r17" id="body-ref-r17-2" href-manipulated="true">3,14–17</a></sup> and this procedure may have also controlled for or reduced any differences in home-based testing between the cohorts, given that matching was performed on the basis of key sociodemographic factors of the population of Qatar.</div><div role="paragraph">Because the studies were observational, the participants in the investigated cohorts were not unaware of their status, nor was there randomization; therefore, unmeasured or uncontrolled confounding cannot be ruled out. In the studies involving adolescents, the size of the matched cohorts was substantially smaller than the size of the eligible cohorts, largely because of the rapid scale-up of vaccination, a situation that perhaps reduced the representativeness of the cohorts relative to the total population.</div><div role="paragraph">Although the cohorts were matched according to sex, age, nationality, and number of coexisting conditions, such matching was not possible for other factors (e.g., geographic region) because such data were unavailable. Matching was done to control for measured confounders that are known to affect infection exposure in Qatar.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r14 r15 r16 r17" id="body-ref-r17-3" href-manipulated="true">3,14–17</a></sup> Differences due to unmeasured confounders are possible. However, we had estimated that a relaxing of the matching criteria in additional analyses would have increased the size of the adolescent cohorts by approximately 15% but would have led to similar effectiveness estimates. This outcome suggests that there was insensitivity of the matching method to the observed confounders.</div><div role="paragraph">Moreover, the matching prescription had already been investigated in previous studies with different epidemiologic designs and designs that included control groups to test for null effects.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r18 r19 r20 r21" id="body-ref-r21-2" href-manipulated="true">9,18–21</a></sup> These control groups included unvaccinated cohorts that were compared with vaccinated cohorts within 2 weeks after receipt of the first dose,<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r18 r19 r20" id="body-ref-r20-3" href-manipulated="true">9,18–20</a></sup> when vaccine protection is negligible,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup> and cohorts that received the mRNA-1273 vaccine (Moderna) that were compared with those that received the BNT162b2 vaccine, also in the first 2 weeks after receipt of the first dose.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-3" href-manipulated="true" aria-label="Reference 21">21</a></sup> These studies have shown repeatedly and at different times during the pandemic that this matching prescription provides adequate control of the differences in infection exposure,<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r18 r19 r20 r21" id="body-ref-r21-4" href-manipulated="true">9,18–21</a></sup> a finding that suggests that the matching method may also control for differences in infection exposure in the present studies.</div><div role="paragraph">In this observational study, we found that the 10-μg dose of the BNT162b2 vaccine in children was associated with modest and rapidly waning protection against omicron infection. However, the 30-μg dose in adolescents was associated with stronger and more durable protection, a finding that suggests a role for the antigen dose in determining protection. Protection with the 30-μg dose was strong against pre-omicron infection and waned relatively slowly. Age appeared to influence vaccine protection. Our findings suggest the need to reconsider the value and strategies of vaccinating healthy children in the omicron era with the use of currently available vaccines.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="disclaimer" role="paragraph">The contents of this article are solely the responsibility of the authors.</div><div data-type="published/updated" role="paragraph">This article was published on November 2, 2022, at NEJM.org.</div><div role="paragraph">Supported by the <span class="named-content" data-type="funder">Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar</span> and by the <span class="named-content" data-type="funder">Ministry of Public Health in Qatar, Hamad Medical Corporation, and Sidra Medicine</span>. The <span class="named-content" data-type="funder">Qatar Genome Program and Qatar University Biomedical Research Center</span> provided the reagents for the viral genome sequencing.</div><div role="paragraph"><a href="#ap2">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the staffs at the Hamad Medical Corporation, the Ministry of Public Health in Qatar, Primary Health Care Corporation, Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine–Qatar for the diligent efforts and contributions that made this study possible.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2210058_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2210058/suppl_file/nejmoa2210058_appendix.pdf" download="nejmoa2210058_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2210058_appendix.pdf" data-doi="10.1056/NEJMoa2210058">Download</a></li><li>1.14 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2210058_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2210058/suppl_file/nejmoa2210058_disclosures.pdf" download="nejmoa2210058_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2210058_disclosures.pdf" data-doi="10.1056/NEJMoa2210058">Download</a></li><li>374.55 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. <em>N Engl J Med</em> 2020;383:2603-2615.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2034577&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33301246/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605648000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2603-2615&amp;doi=10.1056%2FNEJMoa2034577&amp;pmid=33301246" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] doses of 30 μg and 10 μg, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] when vaccine protection is negligible, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. <em>N Engl J Med</em> 2022;386:35-46.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2116298&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34752019/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000716092400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+BNT162b2+Covid-19+vaccine+in+children+5+to+11+years+of+age.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=35-46&amp;doi=10.1056%2FNEJMoa2116298&amp;pmid=34752019" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] doses of 30 μg and 10 μg, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and adolescents in other countries. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <em>Sci Rep</em> 2021;11:6233-6233.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-021-85428-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33737535/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000667581800033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Characterizing+the+Qatar+advanced-phase+SARS-CoV-2+epidemic.&amp;publication_year=2021&amp;journal=Sci+Rep&amp;pages=6233-6233&amp;doi=10.1038%2Fs41598-021-85428-7&amp;pmid=33737535" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] dominated sequentially by the index virus, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. <em>PLoS Med</em> 2021;18(12):e1003879-e1003879.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1003879" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34914711/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000731436600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Introduction+and+expansion+of+the+SARS-CoV-2+B.1.1.7+variant+and+reinfections+in+Qatar%3A+a+nationally+representative+cohort+study.&amp;publication_year=2021&amp;journal=PLoS+Med&amp;pages=e1003879-e1003879&amp;doi=10.1371%2Fjournal.pmed.1003879&amp;pmid=34914711" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. <em>N Engl J Med</em> 2021;385:2585-2586.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2110300&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34910864/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000730408600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+natural+immunity+against+SARS-CoV-2+reinfection+with+the+beta+variant.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2585-2586&amp;doi=10.1056%2FNEJMc2110300&amp;pmid=34910864" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the B.1.351 (beta) variant, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] databases have been reported previously. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on symptomatic omicron infections. <em>N Engl J Med</em> 2022;387:21-34.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2203965&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35704396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000812345400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+previous+infection+and+vaccination+on+symptomatic+omicron+infections.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=21-34&amp;doi=10.1056%2FNEJMoa2203965&amp;pmid=35704396" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] (omicron) subvariants BA.1 and BA.2, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] among children 5 to 11 years of age. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] evidence of the omicron variant in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] 2021 (onset of the omicron wave in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] and BA.2 subvariants in mid-January 2022. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] Figure 2B). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] BA.1, BA.2, BA.4, or BA.5 subvariants. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] adolescents paralleled those among adults, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. <em>N Engl J Med</em> 2022;387:1620-1622.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2209306&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/36198139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000933384700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Protective+effect+of+previous+SARS-CoV-2+infection+against+omicron+BA.4+and+BA.5+subvariants.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1620-1622&amp;doi=10.1056%2FNEJMc2209306&amp;pmid=36198139" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and the omicron subvariants BA.4 and BA.5, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and BA.2 subvariants in mid-January 2022. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] BA.1, BA.2, BA.4, or BA.5 subvariants. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar. <em>Nat Med</em> 2021;27:2136-2143.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-021-01583-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34728831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000713960400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+and+mRNA-1273+COVID-19+vaccine+effectiveness+against+the+SARS-CoV-2+delta+variant+in+Qatar.&amp;publication_year=2021&amp;journal=Nat+Med&amp;pages=2136-2143&amp;doi=10.1038%2Fs41591-021-01583-4&amp;pmid=34728831" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] dominated by the B.1.617.2 (delta) variant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] especially delta variants were predominant. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. <em>N Engl J Med</em> 2021;385(24):e83-e83.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2114114&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34614327/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000704119600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Waning+of+BNT162b2+vaccine+protection+against+SARS-CoV-2+infection+in+Qatar.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=e83-e83&amp;doi=10.1056%2FNEJMoa2114114&amp;pmid=34614327" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] especially delta variants were predominant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] adolescents paralleled those among adults, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. <em>N Engl J Med</em> 2022;386:1804-1816.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2200797&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35263534/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000766309700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+mRNA+vaccine+boosters+against+SARS-CoV-2+omicron+infection+in+Qatar.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1804-1816&amp;doi=10.1056%2FNEJMoa2200797&amp;pmid=35263534" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] studies emulating randomized target trials </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the second dose. To ensure exchangeability, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] among children 5 to 11 years of age. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] evidence of the omicron variant in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] 2021 (onset of the omicron wave in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] and BA.2 subvariants in mid-January 2022. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] Figure 2B). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] BA.1, BA.2, BA.4, or BA.5 subvariants. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. <em>Am J Epidemiol</em> 2016;183:758-764.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/aje/kwv254" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26994063/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374475100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Using+big+data+to+emulate+a+target+trial+when+a+randomized+trial+is+not+available.&amp;publication_year=2016&amp;journal=Am+J+Epidemiol&amp;pages=758-764&amp;doi=10.1093%2Faje%2Fkwv254&amp;pmid=26994063" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">World Health Organization. Living guidance for clinical management of COVID-19. 2021 (<a href="https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2">https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Living+guidance+for+clinical+management+of+COVID-19.&amp;publication_year=2021" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the incidence of infection or of severe, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] critical, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] being severe (acute care hospitalization), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in the intensive care unit), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] too few severe, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] critical, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. April 20, 2020 (<a href="https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death">https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+guidelines+for+certification+and+classification+%28coding%29+of+COVID-19+as+cause+of+death.&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] or fatal </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or fatal </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] or fatal </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Ayoub HH, Chemaitelly H, Seedat S, et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <em>J Glob Health</em> 2021;11:05005-05005.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7189/jogh.11.05005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33643638/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000692157500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mathematical+modeling+of+the+SARS-CoV-2+epidemic+in+Qatar+and+its+impact+on+the+national+response+to+COVID-19.&amp;publication_year=2021&amp;journal=J+Glob+Health&amp;pages=05005-05005&amp;doi=10.7189%2Fjogh.11.05005&amp;pmid=33643638" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Coyle PV, Chemaitelly H, Ben Hadj Kacem MA, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals. <em>iScience</em> 2021;24(6):102646-102646.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.isci.2021.102646" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34056566/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000667301700075" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+seroprevalence+in+the+urban+population+of+Qatar%3A+an+analysis+of+antibody+testing+on+a+sample+of+112%2C941+individuals.&amp;publication_year=2021&amp;journal=iScience&amp;pages=102646-102646&amp;doi=10.1016%2Fj.isci.2021.102646&amp;pmid=34056566" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Al-Thani MH, Farag E, Bertollini R, et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. <em>Open Forum Infect Dis</em> 2021;8(8):ofab221-ofab221.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ofid/ofab221" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34458388/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000728385400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+infection+is+at+herd+immunity+in+the+majority+segment+of+the+population+of+Qatar.&amp;publication_year=2021&amp;journal=Open+Forum+Infect+Dis&amp;pages=ofab221-ofab221&amp;doi=10.1093%2Fofid%2Fofab221&amp;pmid=34458388" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Jeremijenko A, Chemaitelly H, Ayoub HH, et al. Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. <em>Emerg Infect Dis</em> 2021;27:1343-1352.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2705.204365" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33900174/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000650121700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Herd+immunity+against+severe+acute+respiratory+syndrome+coronavirus+2+infection+in+10+communities%2C+Qatar.&amp;publication_year=2021&amp;journal=Emerg+Infect+Dis&amp;pages=1343-1352&amp;doi=10.3201%2Feid2705.204365&amp;pmid=33900174" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Yassine HM, et al. Pfizer–BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <em>J Travel Med</em> 2021;28(7):taab083-taab083.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/jtm/taab083" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34050372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000711240500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pfizer%E2%80%93BioNTech+mRNA+BNT162b2+Covid-19+vaccine+protection+against+variants+of+concern+after+one+versus+two+doses.&amp;publication_year=2021&amp;journal=J+Travel+Med&amp;pages=taab083-taab083&amp;doi=10.1093%2Fjtm%2Ftaab083&amp;pmid=34050372" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <em>Nat Med</em> 2021;27:1614-1621.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-021-01446-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34244681/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000671528900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=mRNA-1273+COVID-19+vaccine+effectiveness+against+the+B.1.1.7+and+B.1.351+variants+and+severe+COVID-19+disease+in+Qatar.&amp;publication_year=2021&amp;journal=Nat+Med&amp;pages=1614-1621&amp;doi=10.1038%2Fs41591-021-01446-y&amp;pmid=34244681" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Bertollini R. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. <em>N Engl J Med</em> 2022;386:1091-1093.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2119432&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35081294/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000747074600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Waning+mRNA-1273+vaccine+effectiveness+against+SARS-CoV-2+infection+in+Qatar.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1091-1093&amp;doi=10.1056%2FNEJMc2119432&amp;pmid=35081294" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Bertollini R. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. <em>N Engl J Med</em> 2022;386:799-800.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_22_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2117933&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35045222/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000744207200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+mRNA-1273+and+BNT162b2+vaccines+in+Qatar.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=799-800&amp;doi=10.1056%2FNEJMc2117933&amp;pmid=35045222" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. <em>Lancet</em> 2021;398:2093-2100.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)02249-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34756184/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000726564200022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+a+third+dose+of+the+BNT162b2+mRNA+COVID-19+vaccine+for+preventing+severe+outcomes+in+Israel%3A+an+observational+study.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=2093-2100&amp;doi=10.1016%2FS0140-6736%2821%2902249-2&amp;pmid=34756184" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. <em>Vaccine</em> 2014;32:3133-3138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2014.04.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24731817/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336872500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccine+preventable+disease+incidence+as+a+complement+to+vaccine+efficacy+for+setting+vaccine+policy.&amp;publication_year=2014&amp;journal=Vaccine&amp;pages=3133-3138&amp;doi=10.1016%2Fj.vaccine.2014.04.019&amp;pmid=24731817" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Hasan MR, Kalikiri MKR, Mirza F, et al. Real-time SARS-CoV-2 genotyping by high-throughput multiplex PCR reveals the epidemiology of the variants of concern in Qatar. <em>Int J Infect Dis</em> 2021;112:52-54.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ijid.2021.09.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34525398/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000706527200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Real-time+SARS-CoV-2+genotyping+by+high-throughput+multiplex+PCR+reveals+the+epidemiology+of+the+variants+of+concern+in+Qatar.&amp;publication_year=2021&amp;journal=Int+J+Infect+Dis&amp;pages=52-54&amp;doi=10.1016%2Fj.ijid.2021.09.006&amp;pmid=34525398" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar. <em>Nat Commun</em> 2022;13:3082-3082.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-022-30895-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35654888/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000805202900028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Duration+of+mRNA+vaccine+protection+against+SARS-CoV-2+omicron+BA.1+and+BA.2+subvariants+in+Qatar.&amp;publication_year=2022&amp;journal=Nat+Commun&amp;pages=3082-3082&amp;doi=10.1038%2Fs41467-022-30895-3&amp;pmid=35654888" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents aged 12–15 years — PROTECT cohort, July 2021–February 2022. <em>MMWR Morb Mortal Wkly Rep</em> 2022;71:422-428.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm7111e1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35298453/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000773347500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+2-dose+BNT162b2+%28Pfizer+BioNTech%29+mRNA+vaccine+in+preventing+SARS-CoV-2+infection+among+children+aged+5%E2%80%9311+years+and+adolescents+aged+12%E2%80%9315+years+%E2%80%94+PROTECT+cohort%2C+July+2021%E2%80%93February+2022.&amp;publication_year=2022&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=422-428&amp;doi=10.15585%2Fmmwr.mm7111e1&amp;pmid=35298453" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age. <em>N Engl J Med</em> 2022;387:227-236.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2205011&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35767475/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000818615400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+vaccine+effectiveness+against+omicron+in+children+5+to+11+years+of+age.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=227-236&amp;doi=10.1056%2FNEJMoa2205011&amp;pmid=35767475" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Veneti L, Berild JD, Watle SV, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer–BioNTech) vaccine against reported SARS-CoV-2 delta and omicron infection among adolescents, Norway, August 2021 to January 2022. March 25, 2022 (<a href="https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1">https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1</a>). preprint.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccine+effectiveness+with+BNT162b2+%28Comirnaty%2C+Pfizer%E2%80%93BioNTech%29+vaccine+against+reported+SARS-CoV-2+delta+and+omicron+infection+among+adolescents%2C+Norway%2C+August+2021+to+January+2022.&amp;publication_year=2022" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Kildegaard H, Lund LC, Højlund M, Stensballe LG, Pottegård A. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. <em>BMJ</em> 2022;377:e068898-e068898.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35410884/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000821074600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+adverse+events+after+covid-19+in+Danish+children+and+adolescents+and+effectiveness+of+BNT162b2+in+adolescents%3A+cohort+study.&amp;publication_year=2022&amp;journal=BMJ&amp;pages=e068898-e068898&amp;pmid=35410884" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and adolescents in other countries. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] infection among children than among adults </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Sacco C, Del Manso M, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022. <em>Lancet</em> 2022;400:97-103.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(22)01185-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35780801/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000828296600014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+BNT162b2+vaccine+against+SARS-CoV-2+infection+and+severe+COVID-19+in+children+aged+5%E2%80%9311+years+in+Italy%3A+a+retrospective+analysis+of+January%E2%80%93April%2C+2022.&amp;publication_year=2022&amp;journal=Lancet&amp;pages=97-103&amp;doi=10.1016%2FS0140-6736%2822%2901185-0&amp;pmid=35780801" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and adolescents in other countries. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Covid-19 among children and adolescents. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Seedat S, Chemaitelly H, Ayoub HH, et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <em>Sci Rep</em> 2021;11:18182-18182.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-021-97606-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34521903/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000696645100110" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+infection+hospitalization%2C+severity%2C+criticality%2C+and+fatality+rates+in+Qatar.&amp;publication_year=2021&amp;journal=Sci+Rep&amp;pages=18182-18182&amp;doi=10.1038%2Fs41598-021-97606-8&amp;pmid=34521903" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Butt AA, Dargham SR, Loka S, et al. Coronavirus disease 2019 disease severity in children infected with the omicron variant. <em>Clin Infect Dis</em> 2022;75(1):e361-e367.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciac275" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35404391/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000804255300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Coronavirus+disease+2019+disease+severity+in+children+infected+with+the+omicron+variant.&amp;publication_year=2022&amp;journal=Clin+Infect+Dis&amp;pages=e361-e367&amp;doi=10.1093%2Fcid%2Fciac275&amp;pmid=35404391" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Butt AA, Dargham SR, Tang P, et al. COVID-19 disease severity in persons infected with the omicron variant compared with the delta variant in Qatar. <em>J Glob Health</em> 2022;12:05032-05032.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7189/jogh.12.05032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35788085/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=001195709300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=COVID-19+disease+severity+in+persons+infected+with+the+omicron+variant+compared+with+the+delta+variant+in+Qatar.&amp;publication_year=2022&amp;journal=J+Glob+Health&amp;pages=05032-05032&amp;doi=10.7189%2Fjogh.12.05032&amp;pmid=35788085" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer–BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 years — VISION Network, 10 states, April 2021–January 2022. <em>MMWR Morb Mortal Wkly Rep</em> 2022;71:352-358.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm7109e3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35239634/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000770881800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+COVID-19+Pfizer%E2%80%93BioNTech+BNT162b2+mRNA+vaccination+in+preventing+COVID-19-associated+emergency+department+and+urgent+care+encounters+and+hospitalizations+among+nonimmunocompromised+children+and+adolescents+aged+5%E2%80%9317+years+%E2%80%94+VISION+Network%2C+10+states%2C+April+2021%E2%80%93January+2022.&amp;publication_year=2022&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=352-358&amp;doi=10.15585%2Fmmwr.mm7109e3&amp;pmid=35239634" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. <em>N Engl J Med</em> 2022;386:713-723.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_36_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2117995&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35021004/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000741666300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+BNT162b2+vaccine+against+critical+Covid-19+in+adolescents.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=713-723&amp;doi=10.1056%2FNEJMoa2117995&amp;pmid=35021004" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the omicron variant in children and adolescents. <em>N Engl J Med</em> 2022;386:1899-1909.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2202826&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35353976/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000784328700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+protection+against+the+omicron+variant+in+children+and+adolescents.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1899-1909&amp;doi=10.1056%2FNEJMoa2202826&amp;pmid=35353976" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/20"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">20</span></span> • <span property="datePublished">November 17, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1865</span>-<span property="pageEnd">1876</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: November 2, 2022</div><div><b class="core-label">Published in issue</b>: November 17, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/coronavirus" alt="View article keyword Coronavirus" data-interactiontype="article_recirculation_click">Coronavirus</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/immunization" alt="View article keyword Immunization" data-interactiontype="article_recirculation_click">Immunization</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/vaccines" alt="View article keyword Vaccines" data-interactiontype="article_recirculation_click">Vaccines</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Hiam</span> <span property="familyName">Chemaitelly</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sawsan</span> <span property="familyName">AlMukdad</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Houssein H.</span> <span property="familyName">Ayoub</span>, <span property="honorificSuffix">Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2512-6657" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2512-6657</a></span>, <span property="author" typeof="Person"><span property="givenName">Heba N.</span> <span property="familyName">Altarawneh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter</span> <span property="familyName">Coyle</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Patrick</span> <span property="familyName">Tang</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1583-5484" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-1583-5484</a></span>, <span property="author" typeof="Person"><span property="givenName">Hadi M.</span> <span property="familyName">Yassine</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hebah A.</span> <span property="familyName">Al-Khatib</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maria K.</span> <span property="familyName">Smatti</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mohammad R.</span> <span property="familyName">Hasan</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zaina</span> <span property="familyName">Al-Kanaani</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Einas</span> <span property="familyName">Al-Kuwari</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew</span> <span property="familyName">Jeremijenko</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0375-2713" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0375-2713</a></span>, <span property="author" typeof="Person"><span property="givenName">Anvar H.</span> <span property="familyName">Kaleeckal</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ali N.</span> <span property="familyName">Latif</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9011-4391" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9011-4391</a></span>, <span property="author" typeof="Person"><span property="givenName">Riyazuddin M.</span> <span property="familyName">Shaik</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hanan F.</span> <span property="familyName">Abdul-Rahim</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gheyath K.</span> <span property="familyName">Nasrallah</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mohamed G.</span> <span property="familyName">Al-Kuwari</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hamad E.</span> <span property="familyName">Al-Romaihi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adeel A.</span> <span property="familyName">Butt</span>, <span property="honorificSuffix">M.B., B.S.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1118-1826" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1118-1826</a></span>, <span property="author" typeof="Person"><span property="givenName">Mohamed H.</span> <span property="familyName">Al-Thani</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdullatif</span> <span property="familyName">Al-Khal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Roberto</span> <span property="familyName">Bertollini</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Laith J.</span> <span property="familyName">Abu-Raddad</span>, <span property="honorificSuffix">Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0790-0506" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0790-0506</a></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Infectious Disease Epidemiology Group (H.C., S.A., H.N.A., L.J.A.-R.) and the World Health Organization Collaborating Center for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis (H.C., S.A., H.N.A., L.J.A.-R.), Weill Cornell Medicine–Qatar, Cornell University, Qatar Foundation–Education City, the Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University (H.H.A.), and the Biomedical Research Center (P.C., H.M.Y., H.A.A.-K., M.K.S., G.K.N.) and the Departments of Biomedical Science (H.M.Y., H.A.A.-K., M.K.S., G.K.N.) and Public Health (H.F.A.-R., L.J.A.-R.), College of Health Sciences, QU Health, Qatar University, Hamad Medical Corporation (P.C., Z.A.-K., E.A.-K., A.J., A.H.K., A.N.L., R.M.S., A.A.B., A.A.-K.), the Department of Pathology, Sidra Medicine (P.T., M.R.H.), Primary Health Care Corporation (M.G.A.-K.), and the Ministry of Public Health (H.E.A.-R., M.H.A.-T., R.B.) — all in Doha, Qatar; the Departments of Population Health Sciences (H.C., H.N.A., A.A.B., L.J.A.-R.) and Medicine (A.A.B.), Weill Cornell Medicine, Cornell University, New York; and the Wellcome–Wolfson Institute for Experimental Medicine, Queen’s University, Belfast, United Kingdom (P.C.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Chemaitelly can be contacted at <a href="mailto:hsc2001@qatar-med.cornell.edu">hsc2001@qatar-med.cornell.edu</a>. Dr. Abu-Raddad can be contacted at <a href="mailto:lja2002@qatar-med.cornell.edu">lja2002@qatar-med.cornell.edu</a>. Drs. Chemaitelly and Abu-Raddad can also be contacted at the Infectious Disease Epidemiology Group, Weill Cornell Medicine–Qatar, Qatar Foundation–Education City, P.O. Box 24144, Doha, Qatar.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">41</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2210058" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="fc4bd0f1-c6e8-dc8b-bcfe-f133593d1db2"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850" style="display:inline-block;">
                <img alt="Article has an altmetric score of 2022" src="https://badges.altmetric.com/?size=320&amp;score=2022&amp;types=mbvrttt1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_fc4bd0f1-c6e8-dc8b-bcfe-f133593d1db2" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850&amp;tab=news">
          Picked up by <b>21</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850&amp;tab=twitter">
          Posted by <b>3048</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850&amp;tab=reddit">
          Reddited by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=137979850&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>83</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6f7851419128c-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2210058"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2210058%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-20" data-lazyload="false" data-total="41" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hiam Chemaitelly, </li><li class="list-inline-item cited-by__entry__author">Houssein H Ayoub, </li><li class="list-inline-item cited-by__entry__author">Peter Coyle, </li><li class="list-inline-item cited-by__entry__author">Patrick Tang, </li><li class="list-inline-item cited-by__entry__author">Mohammad R Hasan, </li><li class="list-inline-item cited-by__entry__author">Hadi M Yassine, </li><li class="list-inline-item cited-by__entry__author">Asmaa A Al Thani, </li><li class="list-inline-item cited-by__entry__author">Zaina Al-Kanaani, </li><li class="list-inline-item cited-by__entry__author">Einas Al-Kuwari, </li><li class="list-inline-item cited-by__entry__author">Andrew Jeremijenko, </li><li class="list-inline-item cited-by__entry__author">Anvar Hassan Kaleeckal, </li><li class="list-inline-item cited-by__entry__author">Ali Nizar Latif, </li><li class="list-inline-item cited-by__entry__author">Riyazuddin Mohammad Shaik, </li><li class="list-inline-item cited-by__entry__author">Hanan F Abdul-Rahim, </li><li class="list-inline-item cited-by__entry__author">Gheyath K Nasrallah, </li><li class="list-inline-item cited-by__entry__author">Mohamed Ghaith Al-Kuwari, </li><li class="list-inline-item cited-by__entry__author">Hamad Eid Al-Romaihi, </li><li class="list-inline-item cited-by__entry__author">Mohamed H Al-Thani, </li><li class="list-inline-item cited-by__entry__author">Abdullatif Al-Khal, </li><li class="list-inline-item cited-by__entry__author">Roberto Bertollini, </li><li class="list-inline-item cited-by__entry__author">Adeel A Butt, </li><li class="list-inline-item cited-by__entry__author">Laith J Abu-Raddad, </li></ul><span class="cited-by__entry__title">Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar, </span><span class="cited-by__entry__series-title">eLife, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7554/eLife.103690" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7554/eLife.103690</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7554/eLife.103690" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Natalie M. Linton, </li><li class="list-inline-item cited-by__entry__author">Joshua J. Quint, </li><li class="list-inline-item cited-by__entry__author">Jennie Chen, </li><li class="list-inline-item cited-by__entry__author">Cora Hoover, </li><li class="list-inline-item cited-by__entry__author">Seema Jain, </li><li class="list-inline-item cited-by__entry__author">Tomás M. León, </li></ul><span class="cited-by__entry__title">Pediatric SARS-CoV-2 Incidence in California by Vaccination Status, December 2021 to April 2023, </span><span class="cited-by__entry__series-title">Pediatrics Open Science, </span><span class="cited-by__entry__volume"><strong>1</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(1-11), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1542/pedsos.2024-000264" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1542/pedsos.2024-000264</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1542/pedsos.2024-000264" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hiam Chemaitelly, </li><li class="list-inline-item cited-by__entry__author">Houssein H. Ayoub, </li><li class="list-inline-item cited-by__entry__author">Peter Coyle, </li><li class="list-inline-item cited-by__entry__author">Patrick Tang, </li><li class="list-inline-item cited-by__entry__author">Mohammad R. Hasan, </li><li class="list-inline-item cited-by__entry__author">Hadi M. Yassine, </li><li class="list-inline-item cited-by__entry__author">Asmaa A. Al Thani, </li><li class="list-inline-item cited-by__entry__author">Zaina Al-Kanaani, </li><li class="list-inline-item cited-by__entry__author">Einas Al-Kuwari, </li><li class="list-inline-item cited-by__entry__author">Andrew Jeremijenko, </li><li class="list-inline-item cited-by__entry__author">Anvar Hassan Kaleeckal, </li><li class="list-inline-item cited-by__entry__author">Ali Nizar Latif, </li><li class="list-inline-item cited-by__entry__author">Riyazuddin Mohammad Shaik, </li><li class="list-inline-item cited-by__entry__author">Hanan F. Abdul-Rahim, </li><li class="list-inline-item cited-by__entry__author">Gheyath K. Nasrallah, </li><li class="list-inline-item cited-by__entry__author">Mohamed Ghaith Al-Kuwari, </li><li class="list-inline-item cited-by__entry__author">Adeel A. Butt, </li><li class="list-inline-item cited-by__entry__author">Hamad Eid Al-Romaihi, </li><li class="list-inline-item cited-by__entry__author">Mohamed H. Al-Thani, </li><li class="list-inline-item cited-by__entry__author">Abdullatif Al-Khal, </li><li class="list-inline-item cited-by__entry__author">Roberto Bertollini, </li><li class="list-inline-item cited-by__entry__author">Laith J. Abu-Raddad, </li></ul><span class="cited-by__entry__title">Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron, </span><span class="cited-by__entry__series-title">Nature, </span><span class="cited-by__entry__volume"><strong>639</strong>, </span><span class="cited-by__entry__issue">8056, </span><span class="cited-by__entry__page-range">(1024-1031), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41586-024-08511-9" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41586-024-08511-9</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41586-024-08511-9" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michelle Pfaffenlehner, </li><li class="list-inline-item cited-by__entry__author">Max Behrens, </li><li class="list-inline-item cited-by__entry__author">Daniela Zöller, </li><li class="list-inline-item cited-by__entry__author">Kathrin Ungethüm, </li><li class="list-inline-item cited-by__entry__author">Kai Günther, </li><li class="list-inline-item cited-by__entry__author">Viktoria Rücker, </li><li class="list-inline-item cited-by__entry__author">Jens-Peter Reese, </li><li class="list-inline-item cited-by__entry__author">Peter Heuschmann, </li><li class="list-inline-item cited-by__entry__author">Miriam Kesselmeier, </li><li class="list-inline-item cited-by__entry__author">Flavia Remo, </li><li class="list-inline-item cited-by__entry__author">André Scherag, </li><li class="list-inline-item cited-by__entry__author">Harald Binder, </li><li class="list-inline-item cited-by__entry__author">Nadine Binder, </li></ul><span class="cited-by__entry__title">Methodological challenges using routine clinical care data for real-world evidence: a rapid review utilizing a systematic literature search and focus group discussion, </span><span class="cited-by__entry__series-title">BMC Medical Research Methodology, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12874-024-02440-x" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12874-024-02440-x</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12874-024-02440-x" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qiong Wu, </li><li class="list-inline-item cited-by__entry__author">Bingyu Zhang, </li><li class="list-inline-item cited-by__entry__author">Jiayi Tong, </li><li class="list-inline-item cited-by__entry__author">L. Charles Bailey, </li><li class="list-inline-item cited-by__entry__author">H. Timothy Bunnell, </li><li class="list-inline-item cited-by__entry__author">Jiajie Chen, </li><li class="list-inline-item cited-by__entry__author">Elizabeth A. Chrischilles, </li><li class="list-inline-item cited-by__entry__author">Dimitri A. Christakis, </li><li class="list-inline-item cited-by__entry__author">Stephen M. Downs, </li><li class="list-inline-item cited-by__entry__author">Kathryn Hirabayashi, </li><li class="list-inline-item cited-by__entry__author">Aaron D. Mishkin, </li><li class="list-inline-item cited-by__entry__author">Abu S.M. Mosa, </li><li class="list-inline-item cited-by__entry__author">Nathan M. Pajor, </li><li class="list-inline-item cited-by__entry__author">Suchitra Rao, </li><li class="list-inline-item cited-by__entry__author">Hanieh Razzaghi, </li><li class="list-inline-item cited-by__entry__author">Hayden T. Schwenk, </li><li class="list-inline-item cited-by__entry__author">Marion R. Sills, </li><li class="list-inline-item cited-by__entry__author">Huiyuan Wang, </li><li class="list-inline-item cited-by__entry__author">Linbo Wang, </li><li class="list-inline-item cited-by__entry__author">Yudong Wang, </li><li class="list-inline-item cited-by__entry__author">Dazheng Zhang, </li><li class="list-inline-item cited-by__entry__author">Ting Zhou, </li><li class="list-inline-item cited-by__entry__author">Ravi Jhaveri, </li><li class="list-inline-item cited-by__entry__author">Eric J. Tchetgen Tchetgen, </li><li class="list-inline-item cited-by__entry__author">Jeffrey S. Morris, </li><li class="list-inline-item cited-by__entry__author">Christopher B. Forrest, </li><li class="list-inline-item cited-by__entry__author">Yong Chen, </li></ul><span class="cited-by__entry__title">Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents, </span><span class="cited-by__entry__series-title">eClinicalMedicine, </span><span class="cited-by__entry__volume"><strong>79</strong>, </span><span class="cited-by__entry__page-range">(102962), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.eclinm.2024.102962" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.eclinm.2024.102962</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.eclinm.2024.102962" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mary Aglipay, </li><li class="list-inline-item cited-by__entry__author">Jonathon L Maguire, </li><li class="list-inline-item cited-by__entry__author">Sarah Swayze, </li><li class="list-inline-item cited-by__entry__author">Ashleigh Tuite, </li><li class="list-inline-item cited-by__entry__author">Muhammad Mamdani, </li><li class="list-inline-item cited-by__entry__author">Charles Keown-Stoneman, </li><li class="list-inline-item cited-by__entry__author">Catherine S Birken, </li><li class="list-inline-item cited-by__entry__author">Jeffrey C Kwong, </li></ul><span class="cited-by__entry__title">Initial Effectiveness of mRNA-1273 Against SARS-CoV-2 Infection and Hospitalization in Young Children, </span><span class="cited-by__entry__series-title">Open Forum Infectious Diseases, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1093/ofid/ofae718" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/ofid/ofae718</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/ofid/ofae718" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Christiane Dings, </li><li class="list-inline-item cited-by__entry__author">Dominik Selzer, </li><li class="list-inline-item cited-by__entry__author">Nicola Luigi Bragazzi, </li><li class="list-inline-item cited-by__entry__author">Eva Möhler, </li><li class="list-inline-item cited-by__entry__author">Markus Wenning, </li><li class="list-inline-item cited-by__entry__author">Thomas Gehrke, </li><li class="list-inline-item cited-by__entry__author">Ulf Richter, </li><li class="list-inline-item cited-by__entry__author">Alexandra Nonnenmacher, </li><li class="list-inline-item cited-by__entry__author">Folke Brinkmann, </li><li class="list-inline-item cited-by__entry__author">Tobias Rothoeft, </li><li class="list-inline-item cited-by__entry__author">Michael Zemlin, </li><li class="list-inline-item cited-by__entry__author">Thomas Lücke, </li><li class="list-inline-item cited-by__entry__author">Thorsten Lehr, </li></ul><span class="cited-by__entry__title">Effect of vaccinations and school restrictions on the spread of COVID-19 in different age groups in Germany, </span><span class="cited-by__entry__series-title">Infectious Disease Modelling, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(1250-1264), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.idm.2024.07.004" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.idm.2024.07.004</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.idm.2024.07.004" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Westyn Branch-Elliman, </li><li class="list-inline-item cited-by__entry__author">Melissa Zeynep Ertem, </li><li class="list-inline-item cited-by__entry__author">Richard E. Nelson, </li><li class="list-inline-item cited-by__entry__author">Anseh Danesharasteh, </li><li class="list-inline-item cited-by__entry__author">David Berlin, </li><li class="list-inline-item cited-by__entry__author">Lloyd Fisher, </li><li class="list-inline-item cited-by__entry__author">Elissa M. Schechter-Perkins, </li></ul><span class="cited-by__entry__title">Impacts of testing and immunity acquired through vaccination and infection on covid-19 cases in Massachusetts elementary and secondary students, </span><span class="cited-by__entry__series-title">Communications Medicine, </span><span class="cited-by__entry__volume"><strong>4</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1038/s43856-024-00619-3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s43856-024-00619-3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s43856-024-00619-3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Tim K. Tsang, </li><li class="list-inline-item cited-by__entry__author">Sheena G. Sullivan, </li><li class="list-inline-item cited-by__entry__author">Yu Meng, </li><li class="list-inline-item cited-by__entry__author">Francisco Tsz Tsun Lai, </li><li class="list-inline-item cited-by__entry__author">Min Fan, </li><li class="list-inline-item cited-by__entry__author">Xiaotong Huang, </li><li class="list-inline-item cited-by__entry__author">Yun Lin, </li><li class="list-inline-item cited-by__entry__author">Liping Peng, </li><li class="list-inline-item cited-by__entry__author">Chengyao Zhang, </li><li class="list-inline-item cited-by__entry__author">Bingyi Yang, </li><li class="list-inline-item cited-by__entry__author">Kylie E. C. Ainslie, </li><li class="list-inline-item cited-by__entry__author">Benjamin J. Cowling, </li></ul><span class="cited-by__entry__title">Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents, </span><span class="cited-by__entry__series-title">BMC Medicine, </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1186/s12916-024-03597-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12916-024-03597-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12916-024-03597-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">María Eugenia Toledo-Romaní, </li><li class="list-inline-item cited-by__entry__author">Carmen Valenzuela-Silva, </li><li class="list-inline-item cited-by__entry__author">Minerva Montero-Díaz, </li><li class="list-inline-item cited-by__entry__author">Luisa Iñiguez-Rojas, </li><li class="list-inline-item cited-by__entry__author">Meiby Rodríguez-González, </li><li class="list-inline-item cited-by__entry__author">Mery Martínez-Cabrera, </li><li class="list-inline-item cited-by__entry__author">Rinaldo Puga-Gómez, </li><li class="list-inline-item cited-by__entry__author">Angel German-Almeida, </li><li class="list-inline-item cited-by__entry__author">Sonsire Fernández-Castillo, </li><li class="list-inline-item cited-by__entry__author">Yanet Climent-Ruiz, </li><li class="list-inline-item cited-by__entry__author">Darielys Santana-Mederos, </li><li class="list-inline-item cited-by__entry__author">Lissette López-González, </li><li class="list-inline-item cited-by__entry__author">Ileana Morales-Suárez, </li><li class="list-inline-item cited-by__entry__author">Delaram Doroud, </li><li class="list-inline-item cited-by__entry__author">Yury Valdés-Balbín, </li><li class="list-inline-item cited-by__entry__author">Dagmar García-Rivera, </li><li class="list-inline-item cited-by__entry__author">Patrick Van der Stuyft, </li><li class="list-inline-item cited-by__entry__author">Vicente Vérez-Bencomo, </li></ul><span class="cited-by__entry__title">Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study, </span><span class="cited-by__entry__series-title">The Lancet Regional Health - Americas, </span><span class="cited-by__entry__volume"><strong>34</strong>, </span><span class="cited-by__entry__page-range">(100750), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.lana.2024.100750" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.lana.2024.100750</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.lana.2024.100750" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2210058%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-20" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2210058" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2210058" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2210058.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f1.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/91b6836f-3fb0-4481-8cf3-bbe58abadb01/assets/images/large/nejmoa2210058_f1.jpg" height="3438" width="2145" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Omicron Infection in Children 5 to 11 Years of Age, According to Vaccination Status, and Effectiveness of the 10-μg Vaccine Dose.</div><div class="notes"><div role="doc-footnote">Panel A shows the cumulative incidence of infection with the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children 5 to 11 years of age who had received two 10-μg doses of the BNT162b2 vaccine, as compared with unvaccinated children (control). The inset shows the same data on an expanded y axis. Panel B shows the vaccine effectiveness against omicron infection among children who had received two 10-μg doses according to the number of months after the start of follow-up. Follow-up began 14 days after receipt of the second dose. The lower boundary of the 95% confidence interval (𝙸 bar) for the data at month 4 or later has been truncated.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f2.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/2ca9a283-76fc-4f52-8285-094e6aba8277/assets/images/large/nejmoa2210058_f2.jpg" height="3100" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">SARS-CoV-2 Infection in Adolescents 12 to 17 Years of Age, According to Vaccination Status, in the Pre-Omicron and Omicron Studies.</div><div class="notes"><div role="doc-footnote">Shown is the cumulative incidence of SARS-CoV-2 infection among adolescents 12 to 17 years of age who had received two 30-μg doses of the BNT162b2 vaccine, as compared with unvaccinated adolescents (control) in studies assessing data during the period before the omicron variant became prevalent (pre-omicron study, Panel A) and after the omicron variant became prevalent (omicron study, Panel B). In both panels, the inset shows the same data on an enlarged y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f3.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/99857305-9cd9-40c7-8e7b-5ff57b20ddcb/assets/images/large/nejmoa2210058_f3.jpg" height="3438" width="2014" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Effectiveness of the 30-μg Vaccine Dose in Adolescents 12 to 17 Years of Age before and after the Emergence of the Omicron Variant.</div><div class="notes"><div role="doc-footnote">Panel A shows the effectiveness of the 30-μg dose of BNT162b2 vaccine against SARS-CoV-2 infection before the emergence of the omicron variant (pre-omicron study) among adolescents according to the number of months after receipt of the second dose. Follow-up began 14 days after receipt of the second dose. The lower boundary of the 95% confidence interval (𝙸 bar) for the data at month 4 has been truncated. Panel B shows the effectiveness of the 30-μg dose against omicron infection among adolescents according to date of receipt of the second dose. The date groups are shown in the order of increasing time since receipt of the second dose. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2210058/asset/896b4be1-fd3c-4e3f-b58a-b320b8a0f076/assets/images/large/nejmoa2210058_t1.jpg" height="2399" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Full Eligible Cohorts</span></th><th class="txxr-borders" colspan="3"><span>Matched Cohorts<a href="#core-t1fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vaccinated Cohort<br>(N=21,888)</th><th class="xxxx-borders">Control Cohort<br>(N=91,870)</th><th class="xxxx-borders">SMD<a href="#core-t1fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated Cohort<br>(N=18,728)</th><th class="xxxx-borders">Control Cohort<br>(N=18,728)</th><th class="xxxr-borders">SMD<a href="#core-t1fn3" role="doc-noteref">‡</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (IQR) — yr</td><td class="xxxx-borders">8 (7–10)</td><td class="xxxx-borders">8 (6–9)</td><td class="xxxx-borders">0.32<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">8 (7–10)</td><td class="xxxx-borders">8 (7–10)</td><td class="xxxr-borders">0.00<a href="#core-t1fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.36</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">5 yr</td><td class="xxxx-borders">1,874 (8.6)</td><td class="xxxx-borders">17,503 (19.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,802 (9.6)</td><td class="xxxx-borders">1,802 (9.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">6 yr</td><td class="xxxx-borders shading">2,768 (12.6)</td><td class="xxxx-borders shading">14,190 (15.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,512 (13.4)</td><td class="xxxx-borders shading">2,512 (13.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">7 yr</td><td class="xxxx-borders">3,175 (14.5)</td><td class="xxxx-borders">13,526 (14.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,769 (14.8)</td><td class="xxxx-borders">2,769 (14.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">8 yr</td><td class="xxxx-borders shading">3,381 (15.4)</td><td class="xxxx-borders shading">12,555 (13.7)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,850 (15.2)</td><td class="xxxx-borders shading">2,850 (15.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">9 yr</td><td class="xxxx-borders">3,331 (15.2)</td><td class="xxxx-borders">12,099 (13.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,847 (15.2)</td><td class="xxxx-borders">2,847 (15.2)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">10 yr</td><td class="xxxx-borders shading">3,593 (16.4)</td><td class="xxxx-borders shading">10,903 (11.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,946 (15.7)</td><td class="xxxx-borders shading">2,946 (15.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">11 yr</td><td class="xxxx-borders">3,766 (17.2)</td><td class="xxxx-borders">11,094 (12.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,002 (16.0)</td><td class="xxxx-borders">3,002 (16.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Sex — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.01</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Male</td><td class="xxxx-borders">11,026 (50.4)</td><td class="xxxx-borders">46,950 (51.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">9,374 (50.1)</td><td class="xxxx-borders">9,374 (50.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">10,862 (49.6)</td><td class="xxxx-borders shading">44,920 (48.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">9,354 (49.9)</td><td class="xxxx-borders shading">9,354 (49.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Nationality — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1.18</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Bangladeshi</td><td class="xxxx-borders shading">567 (2.6)</td><td class="xxxx-borders shading">1,033 (1.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">373 (2.0)</td><td class="xxxx-borders shading">373 (2.0)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Egyptian</td><td class="xxxx-borders">718 (3.3)</td><td class="xxxx-borders">10,289 (11.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">718 (3.8)</td><td class="xxxx-borders">718 (3.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Filipino</td><td class="xxxx-borders shading">2,918 (13.3)</td><td class="xxxx-borders shading">2,123 (2.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1,542 (8.2)</td><td class="xxxx-borders shading">1,542 (8.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Indian</td><td class="xxxx-borders">12,822 (58.6)</td><td class="xxxx-borders">23,924 (26.0)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11,951 (63.8)</td><td class="xxxx-borders">11,951 (63.8)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nepalese</td><td class="xxxx-borders shading">144 (0.7)</td><td class="xxxx-borders shading">193 (0.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">76 (0.4)</td><td class="xxxx-borders shading">76 (0.4)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Pakistani</td><td class="xxxx-borders">1,227 (5.6)</td><td class="xxxx-borders">5,607 (6.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,190 (6.4)</td><td class="xxxx-borders">1,190 (6.4)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Qatari</td><td class="xxxx-borders shading">128 (0.6)</td><td class="xxxx-borders shading">18,921 (20.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">128 (0.7)</td><td class="xxxx-borders shading">128 (0.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Sri Lankan</td><td class="xxxx-borders">350 (1.6)</td><td class="xxxx-borders">1,096 (1.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">311 (1.7)</td><td class="xxxx-borders">311 (1.7)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Sudanese</td><td class="xxxx-borders shading">95 (0.4)</td><td class="xxxx-borders shading">2,837 (3.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">95 (0.5)</td><td class="xxxx-borders shading">95 (0.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Other<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">2,919 (13.3)</td><td class="xxxx-borders">25,847 (28.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,344 (12.5)</td><td class="xxxx-borders">2,344 (12.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of coexisting conditions — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.11</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">0</td><td class="xxxx-borders">17,954 (82.0)</td><td class="xxxx-borders">71,929 (78.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">16,030 (85.6)</td><td class="xxxx-borders">16,030 (85.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">3,345 (15.3)</td><td class="xxxx-borders shading">15,973 (17.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,362 (12.6)</td><td class="xxxx-borders shading">2,362 (12.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">≥2</td><td class="xbxx-borders">589 (2.7)</td><td class="xbxx-borders">3,968 (4.3)</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">336 (1.8)</td><td class="xbxx-borders">336 (1.8)</td><td class="xbxr-borders">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Shown are the baseline characteristics of the eligible and matched vaccinated and control cohorts in the study of the effectiveness of the 10-μg dose of the BNT162b2 vaccine against infection with a B.1.1.529 (omicron) subvariant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children 5 to 11 years of age. IQR denotes interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Vaccinated and control cohorts were matched in a 1:1 ratio according to sex, age, nationality, number of coexisting conditions, and calendar month of receipt of the second dose of vaccine for the vaccinated participant or the SARS-CoV-2–negative test for the control participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The standardized mean difference (SMD) is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD of 0.1 or less indicates adequate matching.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The SMD is for the mean difference between groups, divided by the pooled standard deviation.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Nationalities were chosen to represent the most populous groups in Qatar.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">This group included up to 140 other nationalities in the unmatched cohorts and 66 other nationalities in the matched cohorts.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics of Children 5 to 11 Years of Age in the Study of Effectiveness of the 10-μg Dose of the BNT162b2 Vaccine against Infection with a SARS-CoV-2 Omicron Subvariant.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2210058/asset/3eaf454a-306a-46e5-8a71-addba10edc20/assets/images/large/nejmoa2210058_t2.jpg" height="1748" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Epidemiologic Measure</th><th class="txxx-borders">Vaccinated<br>Cohort</th><th class="txxx-borders">Control<br>Cohort</th><th class="txxr-borders">Effectiveness<br>(95% CI)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Children 5–11 yr of age, omicron study</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total follow-up — no. of person-wk</td><td class="xxxx-borders">173,451</td><td class="xxxx-borders">173,082</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incidence rate of infection per 10,000 person-wk (95% CI)</td><td class="xxxx-borders shading">10.6 (9.2–12.3)</td><td class="xxxx-borders shading">14.3 (12.7–16.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hazard ratio for infection with an omicron subvariant (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unadjusted analysis</td><td class="xxxx-borders shading">0.74 (0.61–0.90)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">25.7 (10.0–38.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted analysis<a href="#core-t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0.74 (0.61–0.90)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">25.7 (10.0–38.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adolescents 12–17 yr of age, pre-omicron study</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total follow-up — no. of person-wk</td><td class="xxxx-borders">192,309</td><td class="xxxx-borders">185,751</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incidence rate of infection per 10,000 person-wk (95% CI)</td><td class="xxxx-borders shading">3.5 (2.7–4.4)</td><td class="xxxx-borders shading">28.2 (25.8–30.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hazard ratio for infection with a pre-omicron subvariant (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unadjusted analysis</td><td class="xxxx-borders shading">0.13 (0.10–0.16)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">87.5 (83.8–90.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted analysis<a href="#core-t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0.12 (0.10–0.16)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">87.6 (84.0–90.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Adolescents 12–17 yr of age, omicron study</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Total follow-up — no. of person-wk</td><td class="xxxx-borders">338,838</td><td class="xxxx-borders">319,291</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Incidence rate of infection per 10,000 person-wk (95% CI)</td><td class="xxxx-borders shading">74.4 (71.5–77.3)</td><td class="xxxx-borders shading">104.5 (101.0–108.1)</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Hazard ratio for infection with an omicron subvariant (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unadjusted analysis</td><td class="xxxx-borders shading">0.72 (0.69–0.76)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">27.7 (23.8–31.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Adjusted analysis<a href="#core-t2fn1" role="doc-noteref">*</a></td><td class="xbxx-borders">0.69 (0.66–0.73)</td><td class="xbxx-borders">—</td><td class="xbxr-borders">30.6 (26.9–34.1)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The Cox regression analysis was adjusted for sex, age, nationality, number of coexisting conditions, and calendar month of receipt of the second vaccine dose for the vaccinated participant or the SARS-CoV-2–negative test for the control participant.</div></div></div></figcaption></a><figcaption><div class="caption">Effectiveness of the BNT162b2 Vaccine against SARS-CoV-2 Infection among Children and Adolescents in Qatar.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2210058/asset/0ff1ebcf-49d2-49c9-ade1-3018307b0630/assets/images/large/nejmoa2210058_t3.jpg" height="2599" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="6"><span>Pre-Omicron Study</span></th><th class="txxr-borders" colspan="6"><span>Omicron Study</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="3"><span>Full Eligible Cohorts</span></th><th class="xxxx-borders" colspan="3"><span>Matched Cohorts<a href="#core-t3fn2" role="doc-noteref">†</a></span></th><th class="xxxx-borders" colspan="3"><span>Full Eligible Cohorts</span></th><th class="xxxr-borders" colspan="3"><span>Matched Cohorts<a href="#core-t3fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=81,647)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=66,006)</th><th class="xxxx-borders">SMD<a href="#core-t3fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=23,317)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=23,317)</th><th class="xxxx-borders">SMD<a href="#core-t3fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=89,505)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=86,280)</th><th class="xxxx-borders">SMD<a href="#core-t3fn3" role="doc-noteref">‡</a></th><th class="xxxx-borders">Vaccinated<br>Cohort<br>(N=17,903)</th><th class="xxxx-borders">Control<br>Cohort<br>(N=17,903)</th><th class="xxxr-borders">SMD<a href="#core-t3fn3" role="doc-noteref">‡</a></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median (IQR) — yr</td><td class="xxxx-borders">15 (14–16)</td><td class="xxxx-borders">14 (12–15)</td><td class="xxxx-borders">0.50<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">14 (13–16)</td><td class="xxxx-borders">14 (13–16)</td><td class="xxxx-borders">0.00<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">15 (13–16)</td><td class="xxxx-borders">14 (12–15)</td><td class="xxxx-borders">0.47<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">13 (12–15)</td><td class="xxxx-borders">13 (12–15)</td><td class="xxxr-borders">0.00<a href="#core-t3fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.71</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.00</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.64</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">12 yr</td><td class="xxxx-borders">3,174 (3.9)</td><td class="xxxx-borders">18,636 (28.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,767 (11.9)</td><td class="xxxx-borders">2,767 (11.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">7,865 (8.8)</td><td class="xxxx-borders">28,852 (33.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">6,003 (33.5)</td><td class="xxxx-borders">6,003 (33.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">13 yr</td><td class="xxxx-borders shading">16,581 (20.3)</td><td class="xxxx-borders shading">11,190 (17.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5,767 (24.7)</td><td class="xxxx-borders shading">5,767 (24.7)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">17,713 (19.8)</td><td class="xxxx-borders shading">13,530 (15.7)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,389 (18.9)</td><td class="xxxx-borders shading">3,389 (18.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">14 yr</td><td class="xxxx-borders">16,427 (20.1)</td><td class="xxxx-borders">10,382 (15.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">4,535 (19.4)</td><td class="xxxx-borders">4,535 (19.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">17,218 (19.2)</td><td class="xxxx-borders">12,403 (14.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,677 (15.0)</td><td class="xxxx-borders">2,677 (15.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">15 yr</td><td class="xxxx-borders shading">15,675 (19.2)</td><td class="xxxx-borders shading">9,861 (14.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,870 (16.6)</td><td class="xxxx-borders shading">3,870 (16.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">16,259 (18.2)</td><td class="xxxx-borders shading">11,866 (13.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,254 (12.6)</td><td class="xxxx-borders shading">2,254 (12.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">16 yr</td><td class="xxxx-borders">14,998 (18.4)</td><td class="xxxx-borders">8,257 (12.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,734 (11.7)</td><td class="xxxx-borders">2,734 (11.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">15,447 (17.3)</td><td class="xxxx-borders">10,136 (11.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,790 (10.0)</td><td class="xxxx-borders">1,790 (10.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">17 yr</td><td class="xxxx-borders shading">14,792 (18.1)</td><td class="xxxx-borders shading">7,680 (11.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,644 (15.6)</td><td class="xxxx-borders shading">3,644 (15.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">15,003 (16.8)</td><td class="xxxx-borders shading">9,493 (11.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1,790 (10.0)</td><td class="xxxx-borders shading">1,790 (10.0)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.00</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">41,919 (51.3)</td><td class="xxxx-borders shading">34,594 (52.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">12,083 (51.8)</td><td class="xxxx-borders shading">12,083 (51.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">45,936 (51.3)</td><td class="xxxx-borders shading">44,941 (52.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">9,258 (51.7)</td><td class="xxxx-borders shading">9,258 (51.7)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Female</td><td class="xxxx-borders">39,728 (48.7)</td><td class="xxxx-borders">31,412 (47.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">11,234 (48.2)</td><td class="xxxx-borders">11,234 (48.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">43,569 (48.7)</td><td class="xxxx-borders">41,339 (47.9)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8,645 (48.3)</td><td class="xxxx-borders">8,645 (48.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Nationality — no. (%)<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.26</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.00</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0.24</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Bangladeshi</td><td class="xxxx-borders">1,054 (1.3)</td><td class="xxxx-borders">967 (1.5)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">391 (1.7)</td><td class="xxxx-borders">391 (1.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1,182 (1.3)</td><td class="xxxx-borders">1,521 (1.8)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">414 (2.3)</td><td class="xxxx-borders">414 (2.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Egyptian</td><td class="xxxx-borders shading">8,894 (10.9)</td><td class="xxxx-borders shading">7,538 (11.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3,379 (14.5)</td><td class="xxxx-borders shading">3,379 (14.5)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">9,835 (11.0)</td><td class="xxxx-borders shading">9,460 (11.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,051 (11.5)</td><td class="xxxx-borders shading">2,051 (11.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Filipino</td><td class="xxxx-borders">3,029 (3.7)</td><td class="xxxx-borders">1,118 (1.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">280 (1.2)</td><td class="xxxx-borders">280 (1.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,372 (3.8)</td><td class="xxxx-borders">1,896 (2.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">345 (1.9)</td><td class="xxxx-borders">345 (1.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Indian</td><td class="xxxx-borders shading">12,943 (15.9)</td><td class="xxxx-borders shading">6,569 (10.0)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,812 (12.1)</td><td class="xxxx-borders shading">2,812 (12.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">15,084 (16.9)</td><td class="xxxx-borders shading">9,434 (10.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2,735 (15.3)</td><td class="xxxx-borders shading">2,735 (15.3)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Nepalese</td><td class="xxxx-borders">102 (0.1)</td><td class="xxxx-borders">46 (0.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">9 (&lt;0.1)</td><td class="xxxx-borders">9 (&lt;0.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">120 (0.1)</td><td class="xxxx-borders">76 (0.1)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">7 (&lt;0.1)</td><td class="xxxx-borders">7 (&lt;0.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Pakistani</td><td class="xxxx-borders shading">5,089 (6.2)</td><td class="xxxx-borders shading">2,876 (4.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">982 (4.2)</td><td class="xxxx-borders shading">982 (4.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5,622 (6.3)</td><td class="xxxx-borders shading">3,932 (4.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1,051 (5.9)</td><td class="xxxx-borders shading">1,051 (5.9)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Qatari</td><td class="xxxx-borders">22,927 (28.1)</td><td class="xxxx-borders">22,196 (33.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">7,531 (32.3)</td><td class="xxxx-borders">7,531 (32.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">24,210 (27.0)</td><td class="xxxx-borders">26,578 (30.8)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">5,024 (28.1)</td><td class="xxxx-borders">5,024 (28.1)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Sri Lankan</td><td class="xxxx-borders shading">603 (0.7)</td><td class="xxxx-borders shading">260 (0.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">73 (0.3)</td><td class="xxxx-borders shading">73 (0.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">700 (0.8)</td><td class="xxxx-borders shading">494 (0.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">100 (0.6)</td><td class="xxxx-borders shading">100 (0.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Sudanese</td><td class="xxxx-borders">3,130 (3.8)</td><td class="xxxx-borders">2,253 (3.4)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">829 (3.6)</td><td class="xxxx-borders">829 (3.6)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,395 (3.8)</td><td class="xxxx-borders">2,855 (3.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">616 (3.4)</td><td class="xxxx-borders">616 (3.4)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other<a href="#core-t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">23,876 (29.2)</td><td class="xxxx-borders shading">22,183 (33.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">7,031 (30.2)</td><td class="xxxx-borders shading">7,031 (30.2)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">25,985 (29.0)</td><td class="xxxx-borders shading">30,034 (34.8)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5,560 (31.1)</td><td class="xxxx-borders shading">5,560 (31.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">No. of coexisting conditions — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.02</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.00</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.06</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">0.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">64,614 (79.1)</td><td class="xxxx-borders shading">52,741 (79.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">19,183 (82.3)</td><td class="xxxx-borders shading">19,183 (82.3)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">71,144 (79.5)</td><td class="xxxx-borders shading">70,646 (81.9)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">15,185 (84.8)</td><td class="xxxx-borders shading">15,185 (84.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">1 or 2</td><td class="xxxx-borders">13,478 (16.5)</td><td class="xxxx-borders">10,344 (15.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3,309 (14.2)</td><td class="xxxx-borders">3,309 (14.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">14,592 (16.3)</td><td class="xxxx-borders">12,239 (14.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">2,208 (12.3)</td><td class="xxxx-borders">2,208 (12.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">≥3</td><td class="xbxx-borders shading">3,555 (4.4)</td><td class="xbxx-borders shading">2,921 (4.4)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">825 (3.5)</td><td class="xbxx-borders shading">825 (3.5)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">3,769 (4.2)</td><td class="xbxx-borders shading">3,395 (3.9)</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">510 (2.8)</td><td class="xbxx-borders shading">510 (2.8)</td><td class="xbxr-borders shading">&nbsp;</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Shown are the baseline characteristics of the eligible and matched cohorts in the studies of the effectiveness of the 30-μg dose of the BNT162b2 vaccine among adolescents 12 to 17 years of age against infection with a pre-omicron variant of SARS-CoV-2 and against infection with an omicron subvariant.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Vaccinated and control cohorts were matched in a 1:1 ratio according to sex, age, nationality, number of coexisting conditions, and calendar month of receipt of the second vaccine dose for the vaccinated participant or the SARS-CoV-2–negative test for the control participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">The SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD of 0.1 or less indicates adequate matching.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">The SMD is for the mean difference between groups, divided by the pooled standard deviation.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">Nationalities were chosen to represent the most populous groups in Qatar.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">In the pre-omicron study, this group included up to 135 other nationalities in the unmatched cohorts and 75 other nationalities in the matched cohorts. In the omicron study, this group included up to 143 other nationalities in the unmatched cohorts and 73 other nationalities in the matched cohorts.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics of Adolescents 12 to 17 Years of Age in Two Studies of Effectiveness of the 30-μg Dose of the BNT162b2 Vaccine.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2210058_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2210058</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. <em>N Engl J Med</em> 2020;383:2603-2615.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2034577&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33301246/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605648000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2603-2615&amp;doi=10.1056%2FNEJMoa2034577&amp;pmid=33301246" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] doses of 30 μg and 10 μg, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] when vaccine protection is negligible, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. <em>N Engl J Med</em> 2022;386:35-46.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2116298&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34752019/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000716092400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+BNT162b2+Covid-19+vaccine+in+children+5+to+11+years+of+age.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=35-46&amp;doi=10.1056%2FNEJMoa2116298&amp;pmid=34752019" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] doses of 30 μg and 10 μg, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and adolescents in other countries. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <em>Sci Rep</em> 2021;11:6233-6233.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-021-85428-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33737535/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000667581800033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Characterizing+the+Qatar+advanced-phase+SARS-CoV-2+epidemic.&amp;publication_year=2021&amp;journal=Sci+Rep&amp;pages=6233-6233&amp;doi=10.1038%2Fs41598-021-85428-7&amp;pmid=33737535" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] dominated sequentially by the index virus, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: a nationally representative cohort study. <em>PLoS Med</em> 2021;18(12):e1003879-e1003879.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1003879" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34914711/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000731436600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Introduction+and+expansion+of+the+SARS-CoV-2+B.1.1.7+variant+and+reinfections+in+Qatar%3A+a+nationally+representative+cohort+study.&amp;publication_year=2021&amp;journal=PLoS+Med&amp;pages=e1003879-e1003879&amp;doi=10.1371%2Fjournal.pmed.1003879&amp;pmid=34914711" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. <em>N Engl J Med</em> 2021;385:2585-2586.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2110300&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34910864/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000730408600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+natural+immunity+against+SARS-CoV-2+reinfection+with+the+beta+variant.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2585-2586&amp;doi=10.1056%2FNEJMc2110300&amp;pmid=34910864" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the B.1.351 (beta) variant, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] databases have been reported previously. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection and vaccination on symptomatic omicron infections. <em>N Engl J Med</em> 2022;387:21-34.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2203965&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35704396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000812345400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+previous+infection+and+vaccination+on+symptomatic+omicron+infections.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=21-34&amp;doi=10.1056%2FNEJMoa2203965&amp;pmid=35704396" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] (omicron) subvariants BA.1 and BA.2, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] among children 5 to 11 years of age. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] evidence of the omicron variant in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] 2021 (onset of the omicron wave in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] and BA.2 subvariants in mid-January 2022. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] Figure 2B). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] BA.1, BA.2, BA.4, or BA.5 subvariants. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] adolescents paralleled those among adults, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. <em>N Engl J Med</em> 2022;387:1620-1622.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2209306&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/36198139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000933384700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Protective+effect+of+previous+SARS-CoV-2+infection+against+omicron+BA.4+and+BA.5+subvariants.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1620-1622&amp;doi=10.1056%2FNEJMc2209306&amp;pmid=36198139" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and the omicron subvariants BA.4 and BA.5, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and BA.2 subvariants in mid-January 2022. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] BA.1, BA.2, BA.4, or BA.5 subvariants. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar. <em>Nat Med</em> 2021;27:2136-2143.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-021-01583-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34728831/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000713960400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+and+mRNA-1273+COVID-19+vaccine+effectiveness+against+the+SARS-CoV-2+delta+variant+in+Qatar.&amp;publication_year=2021&amp;journal=Nat+Med&amp;pages=2136-2143&amp;doi=10.1038%2Fs41591-021-01583-4&amp;pmid=34728831" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] dominated by the B.1.617.2 (delta) variant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] especially delta variants were predominant. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. <em>N Engl J Med</em> 2021;385(24):e83-e83.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2114114&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34614327/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000704119600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Waning+of+BNT162b2+vaccine+protection+against+SARS-CoV-2+infection+in+Qatar.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=e83-e83&amp;doi=10.1056%2FNEJMoa2114114&amp;pmid=34614327" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] especially delta variants were predominant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] adolescents paralleled those among adults, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. <em>N Engl J Med</em> 2022;386:1804-1816.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2200797&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35263534/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000766309700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+mRNA+vaccine+boosters+against+SARS-CoV-2+omicron+infection+in+Qatar.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1804-1816&amp;doi=10.1056%2FNEJMoa2200797&amp;pmid=35263534" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] databases have been reported previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] studies emulating randomized target trials </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the second dose. To ensure exchangeability, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] among children 5 to 11 years of age. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] evidence of the omicron variant in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] 2021 (onset of the omicron wave in Qatar </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] and BA.2 subvariants in mid-January 2022. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] Figure 2B). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] BA.1, BA.2, BA.4, or BA.5 subvariants. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. <em>Am J Epidemiol</em> 2016;183:758-764.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/aje/kwv254" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26994063/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374475100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Using+big+data+to+emulate+a+target+trial+when+a+randomized+trial+is+not+available.&amp;publication_year=2016&amp;journal=Am+J+Epidemiol&amp;pages=758-764&amp;doi=10.1093%2Faje%2Fkwv254&amp;pmid=26994063" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">World Health Organization. Living guidance for clinical management of COVID-19. 2021 (<a href="https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2">https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Living+guidance+for+clinical+management+of+COVID-19.&amp;publication_year=2021" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the incidence of infection or of severe, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] critical, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] being severe (acute care hospitalization), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] in the intensive care unit), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] too few severe, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] critical, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. April 20, 2020 (<a href="https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death">https://www.who.int/publications/m/item/international-guidelines-for-certification-and-classification-(coding)-of-covid-19-as-cause-of-death</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+guidelines+for+certification+and+classification+%28coding%29+of+COVID-19+as+cause+of+death.&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] or fatal </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or fatal </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] or fatal </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Ayoub HH, Chemaitelly H, Seedat S, et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <em>J Glob Health</em> 2021;11:05005-05005.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7189/jogh.11.05005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33643638/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000692157500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mathematical+modeling+of+the+SARS-CoV-2+epidemic+in+Qatar+and+its+impact+on+the+national+response+to+COVID-19.&amp;publication_year=2021&amp;journal=J+Glob+Health&amp;pages=05005-05005&amp;doi=10.7189%2Fjogh.11.05005&amp;pmid=33643638" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Coyle PV, Chemaitelly H, Ben Hadj Kacem MA, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals. <em>iScience</em> 2021;24(6):102646-102646.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.isci.2021.102646" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34056566/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000667301700075" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+seroprevalence+in+the+urban+population+of+Qatar%3A+an+analysis+of+antibody+testing+on+a+sample+of+112%2C941+individuals.&amp;publication_year=2021&amp;journal=iScience&amp;pages=102646-102646&amp;doi=10.1016%2Fj.isci.2021.102646&amp;pmid=34056566" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Al-Thani MH, Farag E, Bertollini R, et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. <em>Open Forum Infect Dis</em> 2021;8(8):ofab221-ofab221.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ofid/ofab221" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34458388/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000728385400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+infection+is+at+herd+immunity+in+the+majority+segment+of+the+population+of+Qatar.&amp;publication_year=2021&amp;journal=Open+Forum+Infect+Dis&amp;pages=ofab221-ofab221&amp;doi=10.1093%2Fofid%2Fofab221&amp;pmid=34458388" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Jeremijenko A, Chemaitelly H, Ayoub HH, et al. Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. <em>Emerg Infect Dis</em> 2021;27:1343-1352.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2705.204365" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33900174/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000650121700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Herd+immunity+against+severe+acute+respiratory+syndrome+coronavirus+2+infection+in+10+communities%2C+Qatar.&amp;publication_year=2021&amp;journal=Emerg+Infect+Dis&amp;pages=1343-1352&amp;doi=10.3201%2Feid2705.204365&amp;pmid=33900174" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in SARS-CoV-2 exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to affect infection exposure in Qatar, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to affect infection exposure in Qatar. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Yassine HM, et al. Pfizer–BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <em>J Travel Med</em> 2021;28(7):taab083-taab083.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/jtm/taab083" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34050372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000711240500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pfizer%E2%80%93BioNTech+mRNA+BNT162b2+Covid-19+vaccine+protection+against+variants+of+concern+after+one+versus+two+doses.&amp;publication_year=2021&amp;journal=J+Travel+Med&amp;pages=taab083-taab083&amp;doi=10.1093%2Fjtm%2Ftaab083&amp;pmid=34050372" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <em>Nat Med</em> 2021;27:1614-1621.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-021-01446-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34244681/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000671528900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=mRNA-1273+COVID-19+vaccine+effectiveness+against+the+B.1.1.7+and+B.1.351+variants+and+severe+COVID-19+disease+in+Qatar.&amp;publication_year=2021&amp;journal=Nat+Med&amp;pages=1614-1621&amp;doi=10.1038%2Fs41591-021-01446-y&amp;pmid=34244681" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Bertollini R. Waning mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar. <em>N Engl J Med</em> 2022;386:1091-1093.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2119432&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35081294/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000747074600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Waning+mRNA-1273+vaccine+effectiveness+against+SARS-CoV-2+infection+in+Qatar.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1091-1093&amp;doi=10.1056%2FNEJMc2119432&amp;pmid=35081294" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Abu-Raddad LJ, Chemaitelly H, Bertollini R. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. <em>N Engl J Med</em> 2022;386:799-800.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_22_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMc2117933&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35045222/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000744207200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+mRNA-1273+and+BNT162b2+vaccines+in+Qatar.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=799-800&amp;doi=10.1056%2FNEJMc2117933&amp;pmid=35045222" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of differences in exposure risk in Qatar. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] control groups to test for null effects. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] 2 weeks after receipt of the first dose. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] of the differences in infection exposure, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. <em>Lancet</em> 2021;398:2093-2100.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(21)02249-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34756184/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000726564200022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+a+third+dose+of+the+BNT162b2+mRNA+COVID-19+vaccine+for+preventing+severe+outcomes+in+Israel%3A+an+observational+study.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=2093-2100&amp;doi=10.1016%2FS0140-6736%2821%2902249-2&amp;pmid=34756184" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. <em>Vaccine</em> 2014;32:3133-3138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2014.04.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24731817/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000336872500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccine+preventable+disease+incidence+as+a+complement+to+vaccine+efficacy+for+setting+vaccine+policy.&amp;publication_year=2014&amp;journal=Vaccine&amp;pages=3133-3138&amp;doi=10.1016%2Fj.vaccine.2014.04.019&amp;pmid=24731817" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Hasan MR, Kalikiri MKR, Mirza F, et al. Real-time SARS-CoV-2 genotyping by high-throughput multiplex PCR reveals the epidemiology of the variants of concern in Qatar. <em>Int J Infect Dis</em> 2021;112:52-54.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ijid.2021.09.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34525398/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000706527200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Real-time+SARS-CoV-2+genotyping+by+high-throughput+multiplex+PCR+reveals+the+epidemiology+of+the+variants+of+concern+in+Qatar.&amp;publication_year=2021&amp;journal=Int+J+Infect+Dis&amp;pages=52-54&amp;doi=10.1016%2Fj.ijid.2021.09.006&amp;pmid=34525398" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar. <em>Nat Commun</em> 2022;13:3082-3082.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-022-30895-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35654888/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000805202900028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Duration+of+mRNA+vaccine+protection+against+SARS-CoV-2+omicron+BA.1+and+BA.2+subvariants+in+Qatar.&amp;publication_year=2022&amp;journal=Nat+Commun&amp;pages=3082-3082&amp;doi=10.1038%2Fs41467-022-30895-3&amp;pmid=35654888" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents aged 12–15 years — PROTECT cohort, July 2021–February 2022. <em>MMWR Morb Mortal Wkly Rep</em> 2022;71:422-428.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm7111e1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35298453/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000773347500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+2-dose+BNT162b2+%28Pfizer+BioNTech%29+mRNA+vaccine+in+preventing+SARS-CoV-2+infection+among+children+aged+5%E2%80%9311+years+and+adolescents+aged+12%E2%80%9315+years+%E2%80%94+PROTECT+cohort%2C+July+2021%E2%80%93February+2022.&amp;publication_year=2022&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=422-428&amp;doi=10.15585%2Fmmwr.mm7111e1&amp;pmid=35298453" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age. <em>N Engl J Med</em> 2022;387:227-236.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2205011&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35767475/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000818615400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+vaccine+effectiveness+against+omicron+in+children+5+to+11+years+of+age.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=227-236&amp;doi=10.1056%2FNEJMoa2205011&amp;pmid=35767475" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Veneti L, Berild JD, Watle SV, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer–BioNTech) vaccine against reported SARS-CoV-2 delta and omicron infection among adolescents, Norway, August 2021 to January 2022. March 25, 2022 (<a href="https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1">https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1</a>). preprint.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccine+effectiveness+with+BNT162b2+%28Comirnaty%2C+Pfizer%E2%80%93BioNTech%29+vaccine+against+reported+SARS-CoV-2+delta+and+omicron+infection+among+adolescents%2C+Norway%2C+August+2021+to+January+2022.&amp;publication_year=2022" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Kildegaard H, Lund LC, Højlund M, Stensballe LG, Pottegård A. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. <em>BMJ</em> 2022;377:e068898-e068898.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35410884/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000821074600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+adverse+events+after+covid-19+in+Danish+children+and+adolescents+and+effectiveness+of+BNT162b2+in+adolescents%3A+cohort+study.&amp;publication_year=2022&amp;journal=BMJ&amp;pages=e068898-e068898&amp;pmid=35410884" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and adolescents in other countries. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] infection among children than among adults </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Sacco C, Del Manso M, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022. <em>Lancet</em> 2022;400:97-103.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(22)01185-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35780801/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000828296600014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+BNT162b2+vaccine+against+SARS-CoV-2+infection+and+severe+COVID-19+in+children+aged+5%E2%80%9311+years+in+Italy%3A+a+retrospective+analysis+of+January%E2%80%93April%2C+2022.&amp;publication_year=2022&amp;journal=Lancet&amp;pages=97-103&amp;doi=10.1016%2FS0140-6736%2822%2901185-0&amp;pmid=35780801" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and adolescents in other countries. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Covid-19 among children and adolescents. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Seedat S, Chemaitelly H, Ayoub HH, et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <em>Sci Rep</em> 2021;11:18182-18182.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-021-97606-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34521903/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000696645100110" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+infection+hospitalization%2C+severity%2C+criticality%2C+and+fatality+rates+in+Qatar.&amp;publication_year=2021&amp;journal=Sci+Rep&amp;pages=18182-18182&amp;doi=10.1038%2Fs41598-021-97606-8&amp;pmid=34521903" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Butt AA, Dargham SR, Loka S, et al. Coronavirus disease 2019 disease severity in children infected with the omicron variant. <em>Clin Infect Dis</em> 2022;75(1):e361-e367.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciac275" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35404391/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000804255300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Coronavirus+disease+2019+disease+severity+in+children+infected+with+the+omicron+variant.&amp;publication_year=2022&amp;journal=Clin+Infect+Dis&amp;pages=e361-e367&amp;doi=10.1093%2Fcid%2Fciac275&amp;pmid=35404391" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Butt AA, Dargham SR, Tang P, et al. COVID-19 disease severity in persons infected with the omicron variant compared with the delta variant in Qatar. <em>J Glob Health</em> 2022;12:05032-05032.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7189/jogh.12.05032" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35788085/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=001195709300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=COVID-19+disease+severity+in+persons+infected+with+the+omicron+variant+compared+with+the+delta+variant+in+Qatar.&amp;publication_year=2022&amp;journal=J+Glob+Health&amp;pages=05032-05032&amp;doi=10.7189%2Fjogh.12.05032&amp;pmid=35788085" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer–BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 years — VISION Network, 10 states, April 2021–January 2022. <em>MMWR Morb Mortal Wkly Rep</em> 2022;71:352-358.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm7109e3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35239634/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000770881800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+COVID-19+Pfizer%E2%80%93BioNTech+BNT162b2+mRNA+vaccination+in+preventing+COVID-19-associated+emergency+department+and+urgent+care+encounters+and+hospitalizations+among+nonimmunocompromised+children+and+adolescents+aged+5%E2%80%9317+years+%E2%80%94+VISION+Network%2C+10+states%2C+April+2021%E2%80%93January+2022.&amp;publication_year=2022&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=352-358&amp;doi=10.15585%2Fmmwr.mm7109e3&amp;pmid=35239634" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. <em>N Engl J Med</em> 2022;386:713-723.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_36_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2117995&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35021004/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000741666300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effectiveness+of+BNT162b2+vaccine+against+critical+Covid-19+in+adolescents.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=713-723&amp;doi=10.1056%2FNEJMoa2117995&amp;pmid=35021004" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the omicron variant in children and adolescents. <em>N Engl J Med</em> 2022;386:1899-1909.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2210058&amp;key=10.1056%2FNEJMoa2202826&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35353976/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000784328700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=BNT162b2+protection+against+the+omicron+variant+in+children+and+adolescents.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1899-1909&amp;doi=10.1056%2FNEJMoa2202826&amp;pmid=35353976" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/676323/hepatologist-concorde-medical-northwell-health/?query=fjwp&amp;rid=3059">Hepatologist - Concorde Medical, Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Connecticut</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889351/division-chief-oncology/?query=fjwp&amp;rid=165114">Division Chief - Oncology</a></div></div><div class="nejm-widget_item"><div><span> Bloomington, Indiana</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891396/general-gastroenterologist-position-with-established-team-and-limited-call/?query=fjwf&amp;rid=227336">General Gastroenterologist position with Established Team and Limited Call</a></div></div><div class="nejm-widget_item"><div><span> Paducah, Kentucky</span></div><div><span>Nephrology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/892160/private-practice-nephrology-in-kentucky-j1-friendly-275k-base-compensation-/?query=fjwf&amp;rid=29477">Private Practice Nephrology in Kentucky *J1 friendly, 275K+ Base Compensation*</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Allergy &amp; Clinical Immunology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/774426/seeking-various-allergists-across-northwell-health/?query=fjwp&amp;rid=3059">Seeking various Allergists across Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Indianapolis, Indiana</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876644/iu-health-general-oncologist-in-indianapolis-in/?query=fjwf&amp;rid=227332">IU Health -  General Oncologist in Indianapolis, IN</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2210058&amp;pubId=41284384&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6f7851419128c-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6f7851419128c-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6f7851419128c-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$489999709$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$489999709$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$489999709$--></div></div><div class="mlt-body"><!--?lit$489999709$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$489999709$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$489999709$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$489999709$-->Sep 30, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2113394?query=recirc_Semantic" target="_self">BNT162b2 Covid-19 Vaccine in Adolescents</a></div><div class="mlt-article-authors"><!--?lit$489999709$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$489999709$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$489999709$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$489999709$-->Feb 10, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2118775?query=recirc_Semantic" target="_self">BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age</a></div><div class="mlt-article-authors"><!--?lit$489999709$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$489999709$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$489999709$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$489999709$-->Jul 15, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2107456?query=recirc_Semantic" target="_self">Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents</a></div><div class="mlt-article-authors"><!--?lit$489999709$-->R.W. Frenck, Jr., and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$489999709$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$489999709$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$489999709$-->Jan 06, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116298?query=recirc_Semantic" target="_self">Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age</a></div><div class="mlt-article-authors"><!--?lit$489999709$-->E.B. Walter and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$489999709$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$489999709$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$489999709$-->Feb 16, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211031?query=recirc_Semantic" target="_self">Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age</a></div><div class="mlt-article-authors"><!--?lit$489999709$-->F.M. Muñoz and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2210058?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2210058" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2210058.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2210058"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Covid-19 Vaccine Protection among Children and Adolescents in Qatar</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2211023" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMcp2203385" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Gout</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f1.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/91b6836f-3fb0-4481-8cf3-bbe58abadb01/assets/images/large/nejmoa2210058_f1.jpg" height="3438" width="2145" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Omicron Infection in Children 5 to 11 Years of Age, According to Vaccination Status, and Effectiveness of the 10-μg Vaccine Dose.</div><div class="notes"><div role="doc-footnote">Panel A shows the cumulative incidence of infection with the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among children 5 to 11 years of age who had received two 10-μg doses of the BNT162b2 vaccine, as compared with unvaccinated children (control). The inset shows the same data on an expanded y axis. Panel B shows the vaccine effectiveness against omicron infection among children who had received two 10-μg doses according to the number of months after the start of follow-up. Follow-up began 14 days after receipt of the second dose. The lower boundary of the 95% confidence interval (𝙸 bar) for the data at month 4 or later has been truncated.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f2.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/2ca9a283-76fc-4f52-8285-094e6aba8277/assets/images/large/nejmoa2210058_f2.jpg" height="3100" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">SARS-CoV-2 Infection in Adolescents 12 to 17 Years of Age, According to Vaccination Status, in the Pre-Omicron and Omicron Studies.</div><div class="notes"><div role="doc-footnote">Shown is the cumulative incidence of SARS-CoV-2 infection among adolescents 12 to 17 years of age who had received two 30-μg doses of the BNT162b2 vaccine, as compared with unvaccinated adolescents (control) in studies assessing data during the period before the omicron variant became prevalent (pre-omicron study, Panel A) and after the omicron variant became prevalent (omicron study, Panel B). In both panels, the inset shows the same data on an enlarged y axis.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2210058_f3.jpg"><img src="/cms/10.1056/NEJMoa2210058/asset/99857305-9cd9-40c7-8e7b-5ff57b20ddcb/assets/images/large/nejmoa2210058_f3.jpg" height="3438" width="2014" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Effectiveness of the 30-μg Vaccine Dose in Adolescents 12 to 17 Years of Age before and after the Emergence of the Omicron Variant.</div><div class="notes"><div role="doc-footnote">Panel A shows the effectiveness of the 30-μg dose of BNT162b2 vaccine against SARS-CoV-2 infection before the emergence of the omicron variant (pre-omicron study) among adolescents according to the number of months after receipt of the second dose. Follow-up began 14 days after receipt of the second dose. The lower boundary of the 95% confidence interval (𝙸 bar) for the data at month 4 has been truncated. Panel B shows the effectiveness of the 30-μg dose against omicron infection among adolescents according to date of receipt of the second dose. The date groups are shown in the order of increasing time since receipt of the second dose. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics of Children 5 to 11 Years of Age in the Study of Effectiveness of the 10-μg Dose of the BNT162b2 Vaccine against Infection with a SARS-CoV-2 Omicron Subvariant.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Effectiveness of the BNT162b2 Vaccine against SARS-CoV-2 Infection among Children and Adolescents in Qatar.</div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics of Adolescents 12 to 17 Years of Age in Two Studies of Effectiveness of the 30-μg Dose of the BNT162b2 Vaccine.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/20" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 20</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 17, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2211023" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.L. O’Donoghue and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 17, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2209041" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Spontaneous-Breathing Trials with Pressure-Support Ventilation or a T-Piece</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.W. Thille and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 17, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2206966" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">K. Kayentao and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2210058%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2210058&amp;pubId=41284384&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2210058%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2210058&amp;pubId=41284384&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05556069228957689" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6f7851419128c-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6f7851419128c-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6f7851419128c-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6f7851419128c-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6f7851419128c-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6f7851419128c-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6f7851419128c-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6f7851419128c-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6f7851419128c-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6f7851419128c-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6f784fce4128c',t:'MTc0OTUzODU2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6f784fce4128c&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-transactionid="5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" id="captureIFrame_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" target="captureIFrame_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="capture_screen"><input id="capture_signIn_js_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="js_version"><input id="capture_signIn_transactionId_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" type="hidden" class="capture_transactionId_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="capture_transactionId"><input id="capture_signIn_form_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="form"><input id="capture_signIn_flow_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="flow"><input id="capture_signIn_client_id_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="client_id"><input id="capture_signIn_redirect_uri_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="redirect_uri"><input id="capture_signIn_response_type_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="response_type"><input id="capture_signIn_flow_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="flow_version"><input id="capture_signIn_settings_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="settings_version"><input id="capture_signIn_locale_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="locale"><input id="capture_signIn_recaptcha_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_5ljatmljg7zxzpovdpebngnvtu0cj5qom1vhmzaa" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><mxb-mpawjtgvzcpj></mxb-mpawjtgvzcpj><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2210058?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>